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Abstract	  Previous	  studies	  have	  demonstrated	  that	  infection	  with	  both	  human	  immune	  deficiency	  virus	  (HIV)	  and	  hepatitis	  C	  (HCV)	  is	  associated	  with	  impaired	  cognitive	  function.	  It	  is	  unclear	  whether	  co-­‐infection	  is	  associated	  with	  neuroimaging	  markers	  of	  brain	  dysfunction.	  	  The	  purpose	  of	  the	  present	  study	  was	  to	  compare	  HIV+	  individuals,	  HIV/HCV+	  individuals,	  and	  seronegative	  controls	  using	  diffusion	  tensor	  imaging	  (DTI)	  to	  assess	  the	  microstructural	  integrity	  of	  white	  matter	  tissue.	  	  
Methods:	  	  Twenty-­‐five	  HIV+	  patients,	  25	  HIV/HCV+	  patients,	  and	  25	  seronegative	  controls	  matched	  for	  age	  were	  included	  in	  the	  study.	  All	  participants	  completed	  an	  MRI	  session,	  neuropsychological	  testing,	  and	  an	  evaluation	  of	  clinical	  variables	  including	  liver	  health.	  White	  matter	  regions	  of	  interest	  (ROI)	  were	  determined	  using	  a	  semi-­‐automatic	  method	  based	  on	  individual	  anatomy.	  DTI	  metrics	  including	  mean	  diffusivity	  (MD),	  axial	  diffusivity	  (AD),	  radial	  diffusivity	  (RD),	  and	  fractional	  anisotropy	  (FA)	  were	  compared	  across	  groups	  using	  ANOVA.	  A	  regression	  model	  including	  DTI	  metrics,	  an	  index	  of	  liver	  function,	  and	  self-­‐reported	  physical	  and	  mental	  health	  was	  performed	  to	  determine	  the	  relationship	  between	  those	  variables	  and	  cognitive	  performance	  in	  the	  co-­‐infected	  group.	  	  
Results:	  The	  co-­‐infected	  group	  was	  similar	  to	  the	  mono-­‐infected	  group	  in	  terms	  of	  HIV	  clinical	  variables.	  None	  of	  the	  participants	  met	  criteria	  for	  cirrhosis	  or	  fibrosis	  on	  the	  index	  of	  liver	  function.	  	  There	  were	  no	  differences	  between	  groups	  on	  DTI	  metrics	  in	  the	  frontal	  ROI.	  In	  the	  anterior	  corpus	  callosum	  there	  was	  a	  significant	  difference	  between	  the	  HIV+	  groups	  compared	  to	  controls	  with	  both	  patient	  groups	  having	  lower	  FA	  values.	  	  Additionally,	  the	  HIV/HCV+	  group	  had	  significantly	  higher	  RD	  compared	  to	  controls	  in	  the	  corpus	  callosum,	  particularly	  in	  the	  anterior	  sections.	  Increased	  RD	  in	  the	  corpus	  callosum	  was	  associated	  with	  performance	  on	  executive	  function/working	  memory	  measures	  only	  at	  a	  trend	  level	  (p=0.07)	  in	  the	  co-­‐infected	  group.	  
Conclusions:	  	  Co-­‐infection	  with	  HIV	  and	  HCV	  may	  result	  in	  significant	  alterations	  in	  white	  matter	  structural	  integrity	  as	  measured	  by	  DTI,	  especially	  in	  the	  anterior	  corpus	  callosum.	  The	  effect	  of	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HIV/HCV	  co-­‐infection	  was	  greater	  than	  the	  effect	  of	  HIV	  mono-­‐infection	  compared	  to	  controls	  in	  all	  regions	  sampled.	  These	  results	  suggest	  that	  the	  combined	  effects	  of	  the	  viruses	  in	  the	  brain	  result	  in	  compromised	  white	  matter	  microstructural	  integrity.	  	  




Diffusion	  Tensor	  Imaging	  in	  Human	  Immunodeficiency	  Virus	  and	  Hepatitis	  C	  co-­‐infection	  Human	  immunodeficiency	  virus	  (HIV)	  and	  hepatitis	  C	  virus	  (HCV)	  share	  similar	  routes	  of	  transmission,	  most	  commonly	  through	  intravenous	  drug	  use	  or	  sexual	  contact.	  Approximately	  1/3	  of	  HIV	  patients	  are	  co-­‐infected	  with	  HCV	  (Parsons	  et	  al.,	  2006)	  and	  it	  is	  believed	  that	  as	  many	  as	  90%	  of	  HIV	  infected	  patients,	  who	  acquired	  the	  disease	  through	  intravenous	  drug	  use,	  may	  be	  co-­‐infected	  with	  HCV.	  Liver	  disease	  has	  become	  the	  most	  common	  cause	  of	  death	  in	  HIV	  (Morgello	  et	  al.,	  2005)	  largely	  due	  to	  the	  number	  of	  co-­‐infected	  individuals	  (Clifford,	  Evans,	  Yang,	  &	  Gulick,	  2005).	  	  The	  progression	  from	  fibrosis	  to	  cirrhosis	  of	  the	  liver	  is	  due	  to	  chronic	  inflammatory	  processes	  that	  are	  often	  magnified	  by	  factors	  such	  as	  HIV,	  other	  viruses,	  metabolic	  disorders	  and	  alcohol	  consumption.	  	  A	  recent	  meta-­‐analysis	  by	  Thein	  and	  colleagues	  (Thein,	  Yi,	  Dore,	  &	  Krahn,	  2008)	  reported	  that	  co-­‐infection	  of	  HIV/HCV	  increased	  the	  risk	  to	  develop	  cirrhosis	  by	  a	  factor	  of	  two	  compared	  to	  an	  HCV	  mono-­‐infected	  population.	  Higher	  levels	  of	  HCV-­‐RNA	  have	  been	  found	  in	  co-­‐infected	  individuals	  and	  increased	  inflammation	  of	  the	  liver	  and	  progression	  to	  end-­‐stage	  liver	  disease	  is	  more	  common	  in	  co-­‐infection	  than	  HCV	  mono-­‐infection	  (Blackard	  &	  Sherman,	  2008).	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Both	  hepatitis	  C	  and	  HIV	  are	  each	  known	  to	  be	  associated	  with	  cognitive	  deficits	  (Forton	  et	  al,	  2004;	  Hilsabeck	  et	  al,	  2002;	  McAndrews	  et	  al,	  2005).	  	  It	  is	  important	  to	  determine	  if	  the	  combined	  effects	  of	  HIV	  and	  HCV	  on	  the	  integrity	  of	  the	  brain	  are	  	  different	  from	  either	  infection	  alone,	  particularly	  given	  the	  high	  prevalence	  of	  co-­‐infection	  and	  the	  potential	  additive/synergist	  impact	  on	  health	  outcomes.	  The	  primary	  purpose	  of	  this	  study	  is	  to	  determine	  the	  neuropsychological	  and	  neuroimaging	  impact	  of	  HIV/HCV	  co-­‐infection	  using	  diffusion	  tensor	  imaging	  (DTI).	  I	  hypothesized	  that	  co-­‐infected	  individuals	  would	  exhibit	  significantly	  abnormal	  DTI	  values	  in	  frontal	  white	  matter	  and	  the	  corpus	  callosum	  compared	  to	  HIV	  mono-­‐infected	  individuals	  and	  controls.	  Additionally,	  I	  hypothesized	  that	  DTI	  variables	  would	  predict	  a	  larger	  percentage	  of	  the	  variance	  in	  cognitive	  performance	  than	  substance	  abuse,	  liver	  function,	  or	  self-­‐reported	  physical	  and	  mental	  health.	  
Cognition	  in	  HIV	  
	   In	  the	  early	  years	  of	  HIV,	  AIDS	  dementia	  complex	  was	  a	  common	  diagnosis,	  affecting	  approximately	  30%	  HIV	  patients	  (Heaton	  et	  al,	  2011).	  Dementia	  due	  to	  HIV	  was	  considered	  an	  AIDS-­‐defining	  illness	  and	  a	  cause	  of	  mortality	  in	  many	  patients.	  Since	  the	  advent	  of	  highly	  active	  antiretroviral	  therapy	  (HAART)	  the	  incidence	  of	  dementia	  has	  been	  reduced,	  but	  	  approximately	  30-­‐50%	  of	  patients	  continue	  to	  experience	  milder	  forms	  of	  cognitive	  impairment	  (Heaton	  et	  al,	  2011).	  Practically,	  HAART	  has	  been	  very	  effective	  at	  restoring	  immune	  function,	  but	  have	  limited	  penetration	  into	  the	  central	  nervous	  system	  (CNS;	  Letendre	  et	  al	  2005)	  and	  thus	  the	  brain	  may	  remain	  a	  reservoir	  for	  reproductive	  virus.	  In	  2007	  (Antinori	  et	  al.,	  2007),	  diagnostic	  criteria	  for	  identifying	  HIV-­‐associated	  neurocognitive	  disorders	  (HAND)	  was	  developed,	  resulting	  in	  three	  primary	  categories	  of	  impairment:	  1)	  HAD-­‐	  HIV-­‐associated	  dementia,	  2)	  MND-­‐	  mild	  neurocognitive	  disorder,	  or	  3)	  ANI-­‐	  asymptomatic	  neurocognitive	  impairment.	  	  In	  order	  to	  receive	  a	  diagnosis	  of	  HAND	  an	  individual	  must	  undergo	  neuropsychological	  testing	  in	  at	  least	  seven	  cognitive	  domains	  of	  function,	  score	  below	  local	  norms	  on	  at	  least	  2	  of	  the	  cognitive	  domains,	  and	  have	  an	  assessment	  of	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activities	  of	  daily	  life.	  For	  a	  diagnosis	  of	  HAD	  an	  individual	  must	  score	  greater	  than	  two	  standard	  deviations	  (SD)	  below	  local	  norms	  in	  2	  cognitive	  domains	  and	  demonstrate	  marked	  impairment	  in	  daily	  activities.	  The	  diagnosis	  of	  MND	  requires	  an	  individual	  to	  score	  more	  than	  1	  SD	  below	  the	  mean	  on	  two	  domains,	  and	  have	  mild	  impairment	  in	  daily	  activities.	  An	  individual	  who	  receives	  the	  diagnosis	  of	  ANI	  would	  score	  1	  SD	  below	  normal	  in	  2	  of	  the	  cognitive	  domains,	  but	  demonstrate	  no	  impairment	  in	  daily	  activities.	  In	  all	  cases	  there	  cannot	  be	  any	  other	  explanation	  for	  the	  cognitive	  impairment,	  or	  a	  preexisting	  condition	  that	  may	  explain	  the	  cognitive	  deficit.	  
	   In	  general,	  HIV-­‐associated	  neurocognitive	  disorders	  are	  characterized	  by	  a	  pattern	  of	  deficits	  commonly	  observed	  in	  other	  conditions	  with	  disruption	  of	  frontal-­‐subcortical	  networks.	  These	  deficits	  include	  impairments	  in	  the	  domains	  of	  attention,	  learning,	  psychomotor	  speed,	  working	  memory,	  and	  executive	  functions.	  There	  has	  been	  evidence	  that	  HIV	  is	  present	  in	  higher	  concentrations	  in	  subcortical	  regions	  (Brew,	  1995),	  and	  many	  neuroimaging	  studies	  report	  alterations	  in	  the	  basal	  ganglia	  and	  frontal	  white	  matter	  (For	  review	  see	  Tucker	  et	  al,	  2004;	  see	  Paul,	  Cohen,	  Navia,	  Tashima,	  2002;..	  This	  is	  not	  to	  say	  that	  HIV	  only	  affects	  these	  brain	  regions.	  The	  alterations	  reported	  in	  white	  matter	  have	  a	  diffuse	  pattern	  and	  there	  have	  been	  a	  few	  studies	  to	  indicate	  alterations	  in	  parietal	  (Thompson,	  2005),temporal	  regions	  (McArthur	  et	  al,	  2005,	  Kuper	  et	  al.,	  2011),	  as	  well	  as	  cortical	  gray	  matter	  (Cohen	  et	  al	  2010,	  Kallianpur	  et	  al	  2012,	  Kuper,	  Togwood	  et	  al	  2012;,	  Cohen	  2010).	  	  
Viral	  factors	  	   HIV	  does	  not	  directly	  infect	  neurons.	  Rather,	  immune	  cells	  such	  as	  T-­‐lymphocytes	  (CD4	  cells)	  and	  monocyte-­‐derived	  macrophages	  (MDM)	  are	  the	  primary	  targets	  of	  the	  HIV	  virus	  (Nath,	  2010).	  Once	  HIV	  enters	  the	  body	  it	  can	  attach	  to	  receptors	  on	  CD4	  cells	  and	  through	  endocytosis	  may	  enter	  the	  cell.	  Once	  released	  into	  the	  cell,	  the	  viral	  envelope	  breaks	  apart,	  releasing	  viral	  particles,	  proteins,	  and	  HIV-­‐RNA.	  This	  RNA	  is	  reverse-­‐transcribed	  into	  DNA	  that	  is	  then	  inserted	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into	  the	  cells	  of	  the	  host	  genome,	  referred	  to	  as	  proviral	  DNA.	  As	  the	  virus	  replicates,	  the	  host	  cell	  (usually	  a	  CD4	  T	  lymphocyte)	  is	  weakened	  or	  destroyed.	  MDMs	  are	  less	  susceptible	  to	  the	  viral	  toxins	  and	  can	  provide	  a	  long-­‐term	  sanctuary	  enabling	  continuous	  viral	  production	  over	  the	  life	  of	  these	  cells	  (Meltzer,	  et	  al.,	  1990).	  HIV	  infection	  may	  exist	  in	  a	  host	  for	  years	  without	  before	  an	  individual	  develops	  symptoms	  serious	  enough	  to	  see	  a	  physician...	  Over	  this	  time	  the	  number	  of	  CD4	  cells	  in	  the	  body	  diminishes.	  	  HIV	  is	  thought	  to	  enter	  the	  CNS	  in	  MDMs.	  Once	  inside	  the	  CNS	  these	  MDMs	  can	  produce	  substances	  that	  affect	  the	  integrity	  of	  the	  blood	  brain	  barrier	  (BBB).	  In	  the	  brain,	  there	  are	  few	  CD4	  cells;	  however	  HIV	  infects	  and	  replicates	  in	  MDMs	  and	  microglia	  in	  the	  brain.	  Other	  support	  cells	  in	  the	  brain,	  such	  as	  astrocytes,	  respond	  to	  the	  infiltration	  by	  releasing	  neurotoxins,	  pro-­‐inflammatory	  cytokines,	  and	  reactive	  oxygen	  species	  that	  can	  lead	  to	  disruption	  in	  neurotransmitter	  activity	  and	  ultimately,	  neuronal	  death	  (Lindl,	  Marks,	  Kolson,	  and	  Jordan-­‐Sciutto,	  2010).	  Astrocytes	  may	  be	  infected,	  though	  they	  are	  not	  centers	  of	  active	  HIV	  replication.	  However,	  these	  critical	  support	  cells	  are	  often	  affected	  by	  the	  free	  radicals	  and	  inflammatory	  environment	  in	  a	  manner	  that	  disrupts	  their	  normal	  physiological	  activity	  and	  interaction	  with	  neurons	  (Lindl	  et	  al	  2010).	  	  Viral	  proteins	  and	  particles	  are	  able	  to	  directly	  affect	  neuronal	  function	  and	  have	  been	  shown	  to	  induce	  neuronal	  apoptosis	  (Strazza,	  2011).	  Viral	  proteins	  commonly	  associated	  with	  neuronal	  apoptosis	  are	  gp120,	  gp41,	  Tat,	  Nef,	  and	  Vpr	  (Grovit-­‐Ferbas	  and	  Harris-­‐White,	  2010;	  Jayadev	  and	  Garden,	  2009).	  The	  presence	  of	  these	  particles	  is	  associated	  with	  excitotoxicity	  that	  leads	  to	  neuronal	  death.	  Indirectly,	  these	  proteins	  may	  also	  lead	  to	  the	  production	  of	  other	  molecules	  that	  induce	  neuronal	  apoptosis.	  If	  the	  overall	  HIV	  burden	  can	  be	  minimized	  there	  should	  be	  fewer	  of	  these	  viral	  proteins	  and	  by-­‐products	  in	  the	  CNS,	  resulting	  in	  improved	  neuronal	  function	  (Ellis,	  et	  al.	  2000;	  Epstein	  and	  Gelbard,	  1999).	  Measurements	  of	  CD4,	  Viral	  load,	  and	  proviral	  DNA	  provide	  clinicians	  with	  information	  about	  an	  individual’s	  HIV	  burden,	  and	  they	  can	  provide	  an	  indication	  about	  risk	  for	  HAND.	  Prior	  to	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the	  introduction	  of	  HAART,	  CD4	  count	  was	  commonly	  associated	  with	  cognitive	  status	  (Heaton	  et	  al.,	  2011);	  however,	  more	  recent	  studies	  have	  shown	  that	  current	  CD4	  levels	  are	  not	  a	  reliable	  indicator	  of	  cognitive	  status	  (Ances,	  2011;	  Cysique,	  2010;	  Heaton	  et	  al.,	  2011;	  Robertson	  2010).	  Nadir	  CD4,	  the	  lowest	  recorded	  CD4	  level,	  is	  often	  associated	  with	  HAND	  with	  nadir	  CD4	  count	  (<250cells/μL)	  relating	  to	  increased	  risk	  for	  cognitive	  impairment	  (Jernigan	  et	  al,	  2011).	  Prior	  to	  HAART,	  plasma	  viral	  load	  correlated	  with	  poor	  cognitive	  status	  in	  many	  studies	  (Chang	  et	  al,	  2002;	  McArthur,	  1997;	  Robertson,	  1998;	  Sactor	  et	  al	  2003).	  Individuals	  who	  adhere	  to	  their	  medication	  regimen	  may	  not	  have	  a	  detectable	  plasma	  viral	  load,	  but	  still	  demonstrate	  cognitive	  impairment	  (Robertson	  et	  al.,	  2007),	  which	  is	  why	  current	  viral	  load	  is	  not	  the	  best	  predictor	  of	  cognitive	  impairment	  and	  does	  not	  provide	  information	  about	  latent	  virus	  in	  other	  areas	  of	  the	  body.	  	  
Antiretroviral	  therapy	  	   Although	  HAART	  has	  greatly	  reduced	  the	  burden	  of	  HIV	  in	  the	  periphery,	  there	  may	  still	  be	  lingering	  virus	  in	  the	  CNS.	  The	  incidence	  of	  HAD	  in	  the	  HIV-­‐infected	  population	  has	  dramatically	  decreased;	  however,	  the	  number	  of	  people	  with	  more	  minor	  forms	  of	  cognitive	  dysfunction	  have	  increased	  (Woods,	  Moore,	  Weber,	  and	  Grant,	  2009).	  	  A	  number	  of	  anti-­‐retroviral	  therapies	  do	  not	  easily	  cross	  the	  blood	  brain	  barrier.	  Letendre	  	  (2008)	  indexed	  the	  most	  common	  ART	  therapies	  to	  develop	  a	  rating	  scale	  of	  CNS	  penetration	  referred	  to	  as	  the	  central	  penetration	  effectiveness	  (CPE)	  score,	  to	  determine	  the	  impact	  of	  HAART	  penetration	  on	  cognitive	  status.	  	  Studies	  using	  the	  CPE	  have	  generally	  reported	  improvements	  in	  brain	  function	  with	  greater	  penetration,	  but	  some	  data	  also	  indicate	  that	  higher	  penetration	  may	  be	  toxic	  to	  neural	  integrity,	  possibly	  via	  drug-­‐induced	  mitochondrial	  damage.	  (refs	  (Anthony,	  2009).	  A	  drug	  holiday—a	  period	  of	  time	  during	  which	  no	  HIV	  meds	  are	  taken—could	  be	  beneficial,	  resulting	  in	  improvements	  in	  cognitive	  functioning	  (Robertson,	  2010).	  	  	  	  	   Because	  HAART	  has	  systemic	  effects	  that	  are	  unfavorable	  to	  a	  number	  of	  body	  systems	  over	  long	  periods	  of	  time	  the	  treatment	  is	  often	  not	  initiated	  until	  a	  person’s	  CD4	  count	  drops	  below	  350	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cells/μL.	  Recent	  studies	  have	  prompted	  a	  change	  however,	  indicating	  that	  treatment	  should	  be	  started	  when	  an	  individual’s	  CD4	  count	  reaches	  500	  cells/μL	  (JAMA-­‐Beau	  I	  am	  not	  finding	  this	  source).	  The	  time	  from	  initial	  infection	  until	  the	  point	  where	  CD4	  reaches	  that	  level	  could	  be	  several	  years	  and,	  as	  previously	  stated,	  it	  is	  known	  that	  the	  virus	  is	  present	  in	  the	  brain	  even	  at	  very	  early	  stages	  of	  infection.	  The	  lag	  time	  between	  infection	  and	  treatment	  may	  result	  in	  extended	  inflammatory	  effects	  that	  take	  place	  in	  the	  brain,	  leading	  to	  more	  severe	  impairments.	  	  There	  is	  a	  well-­‐documented	  reciprocal	  relationship	  between	  cognitive	  functioning	  and	  adherence	  to	  HIV	  medication.	  Individuals	  who	  do	  not	  strictly	  adhere	  to	  their	  regimen	  are	  more	  likely	  to	  have	  cognitive	  deficits	  (Catz	  2000;	  Hinkin	  2004,	  McPhail	  and	  Robertson,	  2012).	  	  	  Further,	  prospective	  studies	  have	  demonstrated	  that	  individuals	  with	  poor	  cognitive	  function	  also	  exhibit	  poor	  adherence	  to	  the	  medication	  regimen,	  with	  deficits	  in	  executive	  function	  serving	  as	  the	  strongest	  predictor	  of	  poor	  adherence	  (Ettenhofer,	  Foley,	  Castellon,	  Hinkin,	  2010).	  	  Inconsistent	  use	  of	  medications	  can	  also	  lead	  to	  drug	  resistance	  and	  mutations	  in	  HIV	  that	  are	  less	  responsive	  to	  the	  current	  therapies.	  	  
Substance	  use	  	   It	  is	  common	  for	  individuals	  who	  are	  HIV+	  to	  have	  a	  history	  of	  drug	  use,	  abuse,	  and	  dependence.	  A	  number	  of	  studies	  have	  attempted	  to	  determine	  the	  specific	  interaction	  of	  a	  given	  drug	  and	  HIV	  on	  cognition;	  however,	  given	  that	  most	  drug	  abusers	  are	  polysubstance	  users	  this	  has	  been	  a	  difficult	  task.	  Furthermore,	  it	  is	  important	  to	  assess	  the	  drug	  use	  history	  of	  current	  or	  past	  users	  to	  determine	  the	  individual	  or	  potentially	  additive	  effects	  of	  drug	  use	  on	  cognition	  in	  an	  HIV	  population.	  	  Below	  is	  a	  brief	  review	  of	  drugs	  commonly	  associated	  with	  HIV.	  
Cocaine-­‐	  	  Cocaine	  is	  associated	  with	  a	  number	  of	  factors	  that	  may	  lead	  to	  an	  increased	  risk	  of	  developing	  HAND.	  Cocaine	  has	  been	  implicated	  in	  affecting	  the	  permeability	  of	  the	  BBB,	  allowing	  the	  entry	  of	  virus	  and	  viral	  particles	  into	  the	  CNS	  that	  otherwise	  may	  not	  be	  able	  to	  pass.	  Studies	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have	  shown	  that	  cocaine	  potentiates	  HIV	  replication	  in	  a	  number	  of	  cell	  types,	  and	  upregulates	  receptors	  to	  facilitate	  HIV	  infection	  in	  those	  cells	  (Buch,	  Yao,	  Guo,	  Mori,	  Su,	  and	  Wang,	  2011).	  	  	  Additionally,	  cocaine	  potentiates	  HIV	  protein	  effects	  on	  glial	  cell	  activation	  and	  may	  increase	  the	  cytotoxic	  effects	  of	  gp120	  and	  Tat	  on	  neuronal	  cells	  (Buch	  et	  al.,	  2011).	  
Methamphetamine-­‐	  	  The	  use	  of	  methamphetamine	  (meth)	  is	  associated	  with	  patterns	  of	  neurocognitive	  impairment	  similar	  to	  those	  seen	  in	  HIV+	  patients,	  with	  seronegative	  addicts	  showing	  poor	  performance	  on	  measures	  of	  executive	  function,	  episodic	  memory,	  and	  psychomotor	  skills	  (Kalechstein	  et	  al.,	  2003,	  Scott	  et	  al.,	  2007).	  Neuroimaging	  and	  animal	  studies	  show	  an	  effect	  of	  meth	  in	  HIV-­‐	  individuals	  on	  striatal	  and	  fronto-­‐cortical	  dopamine	  transporters	  and	  activation	  in	  the	  striatum	  and	  parietal	  lobe,	  especially	  with	  NMDA	  receptors	  (Volkow,	  2001).	  Use	  of	  meth	  is	  associated	  with	  depletion	  of	  striatal	  DA	  and	  diminished	  metabolism	  in	  striatal	  regions	  Chang,	  Alicata,	  Ernst,	  Volkow,	  2004;	  Nordahl,	  2005).	  Since	  HIV	  is	  associated	  with	  fronto-­‐striatal	  alterations,	  reduced	  DA	  activity	  and	  similar	  cognitive	  deficits,	  it	  is	  possible	  that	  HIV	  and	  meth	  use	  would	  result	  in	  additive	  neuronal	  dysfunction	  in	  those	  regions.	  At	  least	  one	  study	  (Archibald	  et	  al.,	  2011)	  indicates	  that	  meth	  and	  HIV	  might	  have	  opposing	  effects	  on	  these	  regions,	  such	  that	  the	  co-­‐morbidity	  does	  not	  have	  an	  additive	  effect,	  but	  rather	  mitigates	  the	  effect	  of	  HIV	  or	  meth	  in	  these	  brain	  areas.	  In	  the	  context	  of	  HIV,	  	  neuroimaging	  studies	  indicate	  that	  meth	  use	  is	  associated	  with	  reduced	  cerebral	  blood	  flow	  (Ances	  et	  al.,	  2011)	  and	  abnormalities	  indicating	  glial	  activation	  and	  neuronal	  distress	  Chang,	  Ernst,	  Speck,	  and	  Grob,	  2005).	  Furthermore,	  studies	  indicate	  that	  meth	  may	  affect	  viral	  replication	  specifically	  in	  the	  CNS.	  For	  example,	  in	  a	  simian	  model	  of	  HIV,	  administration	  of	  methamphetamine	  resulted	  in	  an	  increase	  in	  viral	  load	  in	  the	  brain,	  without	  a	  congruent	  increase	  in	  plasma	  viral	  load	  (Marcondes	  2010).	  	  	  
Heroin-­‐	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   Heroin	  is	  associated	  with	  higher	  impulsivity	  (Pau,	  Lee,	  and	  Chan,	  2002)	  that	  may	  persist	  despite	  prolonged	  abstinence	  (Fu	  et	  al.,	  2008).	  Studies	  in	  HIV+	  heroin	  users	  indicate	  similar	  patterns	  of	  impaired	  impulse	  control	  (Martin	  et	  al,	  2004).	  Many	  studies	  report	  that	  heroin	  users	  are	  less	  likely	  to	  adhere	  to	  their	  antiretroviral	  regimen	  (Cohen	  et	  al.,	  2004).	  Additionally	  there	  may	  be	  interactions	  between	  HAART	  and	  heroin,	  or	  methadone,	  resulting	  in	  altered	  levels	  of	  either	  HAART	  or	  methadone,	  depending	  on	  the	  types	  of	  antiretrovirals	  in	  the	  combination	  therapy	  (Faragon,	  2003).	  It	  is	  common	  for	  these	  interactions	  to	  result	  in	  undesirable	  side	  effects	  that	  may	  further	  impact	  adherence	  to	  antiretroviral	  therapy	  (Cohen	  et	  al.,	  2004)	  and	  increase	  the	  risk	  of	  HAND.	  
Smoking/Nicotine-­‐	  	   Smoking	  is	  prevalent	  in	  the	  HIV	  population	  and	  has	  been	  shown	  to	  negate	  some	  of	  the	  benefits	  of	  antiretroviral	  therapy,	  particularly	  in	  women	  (Feldman	  et	  al	  2006).	  At	  least	  one	  study	  has	  shown	  that	  smoking	  also	  is	  predictive	  of	  non-­‐adherence,	  which	  may	  further	  reduce	  the	  benefits	  of	  ART	  (Webb,	  Vanable,	  Carey,	  Blair,	  2009).	  A	  systemic	  review	  of	  the	  literature	  revealed	  that	  smoking	  is	  not	  associated	  with	  HIV	  disease	  progression	  (Furber	  2006).	  	  
Cognition	  and	  HCV	   	  HCV	  is	  a	  chronic	  disease	  in	  the	  majority	  of	  cases	  (Pawlotsky,	  2004)	  and	  has	  been	  found	  to	  result	  in	  cognitive	  deficits.	  	  As	  noted	  above,	  the	  hepatitis	  virus	  attacks	  the	  liver,	  and	  in	  chronic	  infection,	  liver	  damage	  progresses	  to	  fibrosis	  and	  cirrhosis.	  Impaired	  liver	  function	  has	  been	  associated	  with	  a	  number	  of	  cognitive	  deficits	  among	  HCV-­‐infected	  patients	  as	  well	  as	  other	  liver	  diseases	  (Collie,	  2005).	  The	  most	  commonly	  reported	  cognitive	  deficits	  in	  HCV	  patients	  are	  in	  the	  areas	  of	  attention	  (Forton	  et	  al.,	  2002;	  Hilsabeck,	  Hassanein,	  Carlson,	  Ziegler,	  &	  Perry,	  2003;	  Weissenborn,	  Bokemeyer,	  Krause,	  Ennen,	  &	  Ahl,	  2005),	  working	  memory	  (Fontana	  et	  al.,	  2007;	  Forton	  et	  al.,	  2002),	  learning	  (Hilsabeck	  et	  al.,	  2003;	  McAndrews	  et	  al.,	  2005)	  and	  reaction	  time	  (Hilsabeck	  et	  al.,	  2003).	  Interestingly,	  while	  many	  of	  these	  patients	  exhibit	  significant	  liver	  disease,	  a	  current	  review	  of	  cognitive	  impairments	  in	  persons	  with	  HCV	  mono-­‐infection	  revealed	  that	  
Heaps,	  Jodi,	  2012,	  UMSL,	  p.	  	  	  
	  
11	  
deficits	  on	  neuropsychological	  examinations	  have	  been	  found	  even	  in	  the	  absence	  of	  fibrosis	  or	  cirrhosis	  (Perry,	  Hilsabeck,	  &	  Hassanein,	  2008).	  In	  addition	  to	  liver	  disease,	  patients	  with	  HCV	  have	  a	  number	  of	  other	  common	  comorbid	  conditions.	  These	  are	  similar	  to	  HIV	  comorbidities	  and	  include	  substance	  abuse,	  depression,	  anxiety	  and	  fatigue.	  	  As	  noted	  above,	  these	  factors	  have	  also	  been	  associated	  with	  deficits	  in	  cognition	  independent	  of	  HCV,	  and	  could	  be	  considered	  confounds	  when	  examining	  the	  effect	  of	  the	  virus	  on	  cognitive	  function.	  However,	  several	  studies	  report	  no	  relationship	  between	  complaints	  of	  depression,	  anxiety	  and	  fatigue	  and	  cognitive	  dysfunction	  in	  this	  population	  (Fontana	  et	  al.,	  2007;	  Forton	  et	  al.,	  2002;	  Hilsabeck,	  Castellon,	  &	  Hinkin,	  2005;	  Kramer	  et	  al.,	  2005;	  McAndrews	  et	  al.,	  2005;	  Weissenborn	  et	  al.,	  2005).	  Studies	  of	  HCV	  mono-­‐infection	  have	  reported	  cognitive	  deficits	  that	  were	  partially	  explained	  by	  history	  of	  substance	  use	  (Forton,	  Thomas,	  &	  Taylor-­‐Robinson,	  2004),	  while	  other	  studies	  have	  identified	  cognitive	  deficits	  in	  HCV	  patients	  without	  histories	  of	  intravenous	  drug	  use,	  or	  substance	  abuse	  (Perry	  et	  al.,	  2008).	  	  Further,	  Paul	  et	  al.	  (2007)	  reported	  no	  relationship	  between	  substance	  use	  based	  on	  frequency,	  duration,	  and	  chronicity	  of	  use	  and	  cognitive	  performance	  in	  a	  co-­‐infected	  sample,	  suggesting	  that	  substance	  abuse	  may	  not	  fully	  explain	  the	  findings	  of	  greater	  cognitive	  impairment	  in	  this	  population	  	  
Cognition	  in	  HIV/HCV	  co-­‐infection	  
A	  number	  of	  studies	  have	  revealed	  increased	  cognitive	  deficits	  among	  HIV/HCV	  co-­‐infected	  individuals	  compared	  to	  HIV	  mono-­‐infected	  individuals.	  	  A	  recent	  study	  using	  a	  comprehensive	  neuropsychological	  battery	  indicated	  that	  co-­‐infection	  is	  related	  to	  poorer	  neuropsychological	  impairment	  across	  domains	  (Devlin	  et	  al.,	  2012).	  Co-­‐infected	  subjects	  are	  more	  likely	  to	  exhibit	  global	  impairment	  than	  mono-­‐infected	  subjects	  (Cherner	  et	  al.,	  2005;	  Letendre	  et	  al.,	  2005),	  slower	  reaction	  times	  (Martin	  et	  al.,	  2004;	  Perry	  et	  al.,	  2005;	  von	  Giesen	  et	  al.,	  2004),	  abstraction	  deficits	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(Cherner	  et	  al.,	  2005),	  and	  attention	  and	  concentration	  difficulties	  (Perry	  et	  al.,	  2005).	  Murray	  et	  al.	  (2008)	  found	  a	  trend	  for	  lower	  scores	  in	  abstraction	  and	  executive	  function	  in	  a	  co-­‐infected	  group	  compared	  to	  the	  mono-­‐infected	  group.	  Likewise,	  Clifford	  et	  al.	  (2005)	  reported	  that	  HIV/HCV	  co-­‐infected	  patients	  performed	  more	  poorly	  on	  tests	  of	  attention,	  motor	  skills,	  and	  visuomotor	  coordination	  compared	  to	  an	  HIV	  mono-­‐infected	  group,	  even	  after	  controlling	  for	  possible	  confounds.	  One	  additional	  study	  revealed	  that	  both	  HCV	  mono-­‐infected	  and	  HIV/HCV	  co-­‐infected	  patients	  performed	  significantly	  poorer	  on	  tests	  of	  attention,	  visual	  scanning,	  and	  psychomotor	  speed,	  compared	  to	  normal	  controls;	  however,	  the	  difference	  in	  performance	  on	  the	  tasks	  between	  the	  HCV	  mono-­‐infected	  group	  and	  the	  co-­‐infected	  group	  was	  not	  significant	  (Perry	  et	  al.,	  2005).	  	  Chang	  et	  al.	  (2008)	  reported	  impaired	  visual	  memory	  and	  fine	  motor	  skills	  among	  co-­‐infected	  patients	  compared	  to	  HCV	  mono-­‐infected	  patients.	  However,	  a	  recent	  study	  by	  Clifford	  et	  al.	  (2009)	  revealed	  no	  significant	  effect	  of	  HCV	  co-­‐infection	  (in	  controlled	  HIV)	  on	  cognitive	  function	  when	  comparing	  co-­‐infected	  individuals	  with	  a	  detectable	  plasma	  HCV	  viral	  load	  to	  mono	  and	  co-­‐infected	  individuals	  with	  a	  non-­‐detectable	  HCV	  viral	  load.	  However,	  HIV-­‐positive	  individuals	  with	  a	  positive	  HCV	  titer	  performed	  more	  poorly	  than	  HIV-­‐positive	  individuals	  without	  HCV	  antibodies	  on	  2	  of	  3	  neuropsychological	  tests	  administered	  (Trailmaking	  B	  and	  Digit	  Symbol	  Substitution	  test).	  	  These	  findings	  suggest	  that	  the	  effects	  of	  co-­‐infection	  may	  not	  be	  due	  to	  active	  replication	  of	  HCV	  in	  the	  blood,	  but	  rather	  reflect	  chronic	  effects	  of	  HCV	  presence	  in	  the	  brain.	  	  It	  is	  also	  possible	  that	  among	  treated	  patients,	  there	  is	  minimal	  additional	  impact	  of	  co-­‐infection	  on	  cognitive	  status.	  A	  recent	  study	  reviewing	  the	  effect	  of	  HIV/HCV	  coinfection	  did	  not	  report	  any	  increased	  neurocognitive	  impairment	  in	  a	  large	  cohort	  of	  women	  when	  controlling	  for	  other	  confounding	  factors	  (Crystal	  et	  al,	  2012).	  It	  was	  unclear	  if	  the	  co-­‐infected	  individuals	  in	  this	  study	  were	  undergoing	  treatment	  for	  HCV	  at	  the	  time	  of	  testing.	  
Neuroimaging	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HIV	  has	  been	  associated	  with	  structural	  brain	  changes	  in	  both	  the	  pre-­‐	  and	  post-­‐	  HAART	  era.	  An	  early	  autopsy	  study	  examined	  the	  distribution	  of	  HIV	  infected	  cells	  in	  the	  brain	  (Brew,	  1995)	  and	  reported	  that	  the	  areas	  most	  commonly	  infected	  were	  the	  basal	  ganglia,	  corpus	  callosum	  and	  frontal	  white	  matter.	  White	  matter	  was	  two	  to	  three	  times	  more	  likely	  to	  have	  infected	  cells	  than	  the	  cortex.	  This	  and	  other	  early	  autopsy	  studies	  (Hawkins,	  McLaughlin,	  Kendall,	  and	  McDonald,	  1993;	  Kieburtz	  et	  al.,	  1990)	  verified	  MRI	  evidence	  of	  white	  matter	  alterations	  that	  are	  more	  pronounced	  in	  progressed	  disease.	  	  DTI	  is	  a	  neuromaging	  method	  that	  is	  ideally	  suited	  to	  measure	  the	  structural	  integrity	  of	  white	  matter.	  Practically,	  DTI	  is	  a	  calculation	  of	  the	  rate	  of	  water	  diffusion	  along	  a	  gradient	  or	  neural	  tract	  (Correia	  et	  al.,	  2008).	  Axonal	  fibers	  restrict	  the	  random	  movement	  of	  water	  by	  restricting	  the	  flow	  of	  water	  along	  the	  fibers.	  	  Common	  metrics	  from	  DTI	  acquisitions	  include	  fractional	  anisotropy	  (FA)	  and	  mean	  diffusivity	  (MD).	  	  FA	  measures	  the	  amount	  of	  diffusion	  that	  is	  anisotropic,	  or	  directional,	  compared	  to	  the	  diffusion	  that	  is	  isotropic	  or	  random	  and	  MD	  is	  a	  measure	  of	  total	  diffusion	  occurring	  in	  a	  given	  voxel	  (Basser	  &	  Pierpaoli,	  1996).	  More	  recently,	  measures	  of	  axial	  diffusivity	  (AD)	  and	  radial	  diffusivity	  (RD)	  have	  been	  measured	  as	  they	  are	  believed	  to	  provide	  specific	  information	  about	  the	  integrity	  of	  either	  the	  axon	  itself,	  or	  the	  myelin	  surrounding	  the	  axons	  in	  white	  matter	  respectively	  (Song	  et	  al.	  2002).	  	  Specifically,	  AD	  is	  the	  sum	  of	  diffusion	  values	  along	  the	  longitudinal	  plane,	  i.e.	  along	  the	  primary	  eigenvector,	  while	  RD	  is	  the	  sum	  of	  the	  diffusion	  values	  along	  the	  shorter	  axis,	  running	  perpendicular	  to	  the	  primary	  eigenvector.	  Pathological	  factors	  such	  as	  disease,	  trauma	  and	  inflammation	  are	  thought	  to	  impact	  the	  integrity	  and	  organization	  of	  white	  matter	  fibers	  (WMF).	  When	  the	  microstructure	  of	  WMF	  is	  disrupted,	  the	  pattern	  of	  direct	  diffusion	  along	  their	  lengths	  is	  altered,	  which	  is	  expressed	  as	  a	  reduction	  in	  FA,	  and	  typically	  an	  increase	  in	  MD	  and	  potential	  changes	  to	  AD	  or	  RD.	  	  	  
DTI	  in	  HIV	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DTI	  studies	  of	  individuals	  infected	  with	  HIV	  have	  reported	  significantly	  lower	  FA	  in	  the	  frontal	  lobe,	  genu	  of	  the	  corpus	  callosum,	  and	  putamen	  compared	  to	  healthy	  controls	  (Filippi,	  Ulug,	  Ryan,	  Ferrando,	  &	  van	  Gorp,	  2001;	  Thurnher	  et	  al.,	  2005;	  Wu	  et	  al.,	  2006).	  	  In	  addition,	  studies	  have	  reported	  that	  DTI	  metrics	  correlate	  with	  cognitive	  performance	  among	  HIV	  patients.	  	  In	  2004,	  Ragin	  et	  al.	  reported	  that	  decreased	  FA	  correlated	  with	  the	  degree	  of	  cognitive	  impairment	  in	  HIV	  patients	  (Ragin,	  Storey,	  Cohen,	  Epstein,	  &	  Edelman,	  2004).	  The	  same	  group	  later	  reported	  that	  increased	  MD	  in	  the	  putamen	  correlated	  with	  verbal	  memory	  impairment	  while	  decreased	  FA	  in	  this	  structure	  was	  correlated	  with	  global	  cognitive	  impairment	  (Ragin	  et	  al.,	  2005).	  Decreased	  FA	  in	  both	  the	  caudate	  and	  putamen	  was	  related	  to	  visual	  and	  working	  memory	  impairments.	  Additionally,	  the	  researchers	  reported	  a	  significant	  negative	  correlation	  between	  FA	  measures	  in	  the	  centrum	  semiovale	  and	  impaired	  performance	  on	  a	  visuoconstruction	  task.	  Using	  the	  same	  cohort,	  Wu	  and	  colleagues	  (2006)	  reported	  decreased	  FA	  in	  the	  splenium	  and	  genu	  that	  correlated	  to	  motor	  deficits	  and	  visual	  memory	  impairments	  respectively.	  Collectively,	  these	  studies	  indicate	  that	  DTI	  is	  sensitive	  to	  white	  matter	  deficits	  among	  HIV	  patients.	  	  
Neuroimaging	  in	  HCV	  There	  have	  been	  few	  studies	  using	  neuroimaging	  indices	  to	  study	  the	  impact	  of	  HCV	  mono-­‐infection	  on	  cerebral	  integrity.	  Studies	  using	  magnetic	  resonance	  spectroscopy	  (MRS)	  have	  noted	  metabolite	  abnormalities	  in	  non-­‐cirrhotic	  HCV	  patients	  (Forton	  et	  al.,	  2004).	  Weissenborn	  and	  colleagues	  (Weissenborn	  et	  al.,	  2004)	  reported	  decreased	  N-­‐acetyl-­‐aspartate	  (NAA),	  a	  marker	  of	  mature	  neurons,	  in	  a	  group	  of	  non-­‐cirrhotic	  HCV	  patients	  that	  also	  exhibited	  deficits	  in	  attention.	  Further	  research	  has	  revealed	  decreased	  NAA	  in	  frontal	  white	  matter	  in	  a	  group	  of	  methamphetamine	  using	  HCV	  subjects,	  with	  a	  large	  percentage	  demonstrating	  global	  cognitive	  impairment.	  Other	  studies	  have	  reported	  increased	  choline,	  a	  vital	  component	  in	  cell	  membrane	  structure	  and	  function,	  and	  decreased	  NAA	  in	  central	  white	  matter,	  which	  did	  not	  show	  a	  relationship	  to	  fibrosis	  (McAndrews	  et	  al.,	  2005).	  Similar	  metabolite	  abnormalities	  have	  been	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reported	  among	  patients	  with	  HIV	  mono-­‐infection.	  Importantly,	  no	  prior	  studies	  have	  been	  designed	  to	  examine	  neuriomaging	  abnormalities	  among	  patients	  with	  HIV/HCV	  co-­‐infection.	  	  	  
Neuroimaging	  Studies	  of	  HIV-­‐HCV	  Co-­‐Infection	  A	  few	  studies	  have	  examined	  co-­‐infection	  as	  a	  risk	  factor	  for	  neuroimaging	  abnormalities	  (e.g.	  Jernigan	  et	  al.,	  2011,	  Gongvantana	  et	  al,	  2011).	  A	  recent	  study	  revelaed	  that	  co-­‐infected	  individuals	  who	  have	  acute	  HCV	  infection	  performed	  worse	  than	  seronegative	  controls	  on	  neurocognitive	  measures,	  and	  had	  indications	  of	  altered	  brain	  metabolites	  compared	  to	  HIV	  mono-­‐infected	  patients	  (Winston	  et	  al,	  2011).	  A	  recent	  study	  by	  Stebbins	  et	  al.	  (2007)	  utilized	  DTI	  to	  assess	  white	  matter	  integrity	  in	  a	  group	  of	  HIV	  positive	  patients	  compared	  to	  an	  HIV	  negative	  group.	  	  Whole	  brain	  FA	  and	  MD	  did	  not	  differ	  between	  the	  groups	  though	  both	  indices	  differed	  in	  specific	  brain	  regions.	  More	  important	  for	  the	  proposed	  study,	  secondary	  analyses	  revealed	  significantly	  increased	  whole-­‐brain	  MD	  and	  a	  strong	  trend	  for	  reduced	  whole-­‐brain	  FA	  in	  a	  small	  group	  of	  HIV/HCV	  co-­‐infected	  patients	  (n=	  11)	  enrolled	  in	  the	  study.	  	  The	  study	  was	  not	  sufficiently	  powered	  to	  detect	  group	  differences	  based	  on	  co-­‐infection	  status,	  but	  the	  outcomes	  suggest	  that	  DTI	  is	  a	  robust	  index	  of	  brain	  abnormalities	  associated	  with	  co-­‐infection.	  In	  the	  present	  study	  DTI	  was	  employed	  to	  investigate	  differences	  in	  white	  matter	  integrity	  between	  HIV	  mono-­‐infected	  and	  co-­‐infected	  patients.	  Additionally,	  a	  neuropsychological	  battery	  was	  used	  to	  compare	  cognitive	  performance	  between	  the	  mono-­‐	  and	  co-­‐infected	  groups	  and	  to	  determine	  associations	  between	  cognitive	  performance	  and	  DTI	  indices.	  	  
Summary	  	   The	  primary	  purpose	  of	  this	  study	  was	  to	  determine	  the	  neuropsychological	  and	  neuroimaging	  impact	  of	  HIV/hepatitis	  C	  (HCV)	  co-­‐infection	  using	  DTI.	  It	  is	  estimated	  that	  almost	  a	  third	  of	  HIV-­‐positive	  patients	  are	  co-­‐infected	  with	  HCV.	  Most	  studies	  examining	  cognitive	  function	  in	  co-­‐infected	  groups	  report	  worse	  performance	  on	  neuropsychological	  examinations	  in	  a	  number	  of	  cognitive	  domains	  compared	  to	  groups	  with	  HIV	  or	  HCV	  alone	  (Cherner	  et	  al.,	  2005;	  Clifford	  et	  al.,	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2005;	  Hilsabeck	  et	  al.,	  2005;	  Letendre	  et	  al.,	  2005;	  Martin	  et	  al.,	  2004;	  Parsons	  et	  al.,	  2006;	  Ryan,	  Morgello,	  Isaacs,	  Naseer,	  &	  Gerits,	  2004;	  von	  Giesen	  et	  al.,	  2004).	  	  Additionally,	  it	  has	  been	  reported	  that	  co-­‐infected	  persons	  are	  significantly	  more	  likely	  to	  develop	  AIDS	  dementia	  complex	  (Ryan	  et	  al.,	  2004).	  However,	  a	  recent	  study	  of	  patients	  with	  controlled	  HIV	  and	  active	  or	  inactive	  HCV	  viral	  replication	  indicates	  that	  patients	  who	  have	  active	  HCV	  viral	  replication	  exhibit	  no	  added	  impairment	  when	  examined	  using	  a	  brief	  battery	  of	  tests	  (Clifford	  et	  al.,	  2009).	  Despite	  the	  findings	  of	  decreased	  cognitive	  functioning	  in	  co-­‐infection,	  to	  date,	  there	  are	  no	  published	  reports	  using	  neuroimaging	  specifically	  designed	  to	  study	  the	  impact	  of	  co-­‐infection	  in	  the	  brain.	  There	  are	  a	  few	  published	  studies	  that	  utilized	  MRS	  in	  HCV	  that	  identified	  markers	  associated	  with	  the	  breakdown	  of	  white	  matter	  integrity	  (Weissenborn	  et	  al.,	  2004).	  These	  studies	  suggest	  the	  effect	  of	  HCV	  on	  neuronal	  integrity	  as	  seen	  by	  MRS	  is	  similar	  to	  the	  effects	  of	  HIV	  on	  white	  matter	  integrity.	  	  Currently	  there	  are	  a	  limited	  number	  of	  studies	  using	  DTI	  in	  HIV,	  with	  findings	  indicating	  white	  matter	  compromise,	  even	  in	  regions	  of	  “normal	  appearing”	  white	  matter	  (Stebbins	  et	  al.,	  2007).	  The	  neuropsychological	  deficits	  evident	  in	  co-­‐infection	  and	  the	  similar	  findings	  in	  HCV	  using	  MRS	  prompt	  additional	  research	  specifically	  designed	  to	  examine	  the	  effects	  of	  co-­‐infection	  on	  the	  brain.	  DTI	  is	  an	  excellent	  tool	  to	  examine	  co-­‐infection	  in	  the	  brain,	  due	  to	  its	  specific	  sensitivity	  to	  detect	  changes	  in	  white	  matter	  structural	  integrity.	  	  
Methods	  Participants	  	  A	  total	  of	  75	  patients	  (25	  HIV+,	  25	  HIV/HCV+,	  25	  HIV-­‐	  controls)	  were	  included	  in	  the	  study.	  	  A	  total	  of	  25	  HIV/HCV+,	  and	  25	  HIV+	  individuals	  were	  recruited	  for	  the	  purpose	  of	  examining	  cognitive	  and	  neuroimaging	  differences	  between	  HIV+	  and	  HIV/HCV+	  individuals	  with	  a	  previous	  history	  of	  recreational	  drug	  use,	  preferably	  intraveneous	  drug	  use	  (IDU).	  In	  the	  HIV+	  group,	  data	  for	  10	  of	  the	  25	  HIV+	  individuals	  included	  in	  the	  study	  were	  extracted	  from	  an	  archival	  dataset	  with	  similar	  inclusion/exclusion	  criteria	  although	  prior	  drug	  use	  information	  and	  similar	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neuropsychological	  measures	  were	  not	  available	  for	  all	  of	  these	  individuals.	  	  Twenty-­‐five	  controls	  were	  selected	  from	  archival	  data	  and	  matched	  as	  closely	  as	  possible	  for	  age	  and	  education	  to	  the	  HIV/HCV+	  population.	  Detailed	  drug	  use	  histories	  were	  available	  for	  approximately	  half	  of	  all	  the	  controls	  chosen.	  	  	  All	  participants	  were	  initially	  recruited	  by	  referral	  from	  coordinators	  involved	  in	  ongoing	  HIV	  studies	  at	  Washington	  University,	  or	  by	  clinic	  nurses	  at	  either	  the	  Washington	  University	  ACTG	  clinic	  or	  the	  liver	  clinic	  at	  Barnes	  Jewish	  Hospital	  in	  St.	  Louis.	  Coordinators	  and	  clinic	  nurses	  at	  both	  locations	  identified	  patients	  who	  met	  the	  inclusion	  criteria	  for	  the	  study	  by	  reviewing	  medical	  histories	  and	  performing	  an	  initial	  screening.	  Interested	  patients	  were	  provided	  an	  informed	  consent	  form	  to	  review	  and	  were	  asked	  if	  they	  could	  be	  contacted	  about	  participation	  in	  the	  study.	  Each	  participant	  was	  individually	  selected	  and	  approached.	  Participants	  were	  paid	  30	  dollars	  for	  completing	  the	  neuropsychological	  assessments,	  and	  an	  additional	  70	  dollars	  for	  the	  MRI.	  	  
Inclusion/Exclusion	  	   Participants	  ranged	  from	  21-­‐61	  years	  of	  age	  and	  the	  HIV+	  individuals	  were	  required	  to	  be	  on	  stable	  antiretroviral	  therapy	  for	  HIV.	  	  HIV/HCV+	  individuals	  had	  to	  be	  naïve	  to	  treatment	  for	  HCV	  or	  discontinued	  HCV	  treatment	  early	  due	  to	  negative	  side	  effects	  	  Three	  of	  the	  HIV/HCV+	  individuals	  had	  attempted	  HCV	  therapy	  more	  than	  one	  year	  before	  the	  study,	  but	  discontinued	  due	  to	  negative	  side	  effects	  of	  the	  medication.	  	   All	  infected	  participants	  recruited	  had	  a	  previous	  history	  of	  drug	  use,	  including	  injection	  drug	  use	  (IDU)	  but	  were	  not	  actively	  using	  drugs	  at	  the	  time	  of	  testing.	  History	  of	  alcohol	  abuse	  (defined	  by	  DSM-­‐IV	  criteria)	  in	  the	  last	  6	  months	  was	  exclusionary;	  however,	  alcohol	  use	  not	  meeting	  criteria	  for	  abuse	  was	  allowed.	  Participants	  with	  a	  history	  of	  mental	  disorders	  such	  as	  schizophrenia	  or	  bipolar	  disorder,	  and	  learning	  disability	  were	  not	  considered	  for	  the	  study.	  Presence	  of	  other	  potentially	  confounding	  neurological	  disorders	  such	  as	  multiple	  sclerosis,	  demyelinating	  diseases,	  and	  CNS	  conditions,	  a	  history	  of	  opportunistic	  CNS	  infections,	  or	  any	  loss	  of	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consciousness	  lasting	  longer	  than	  30	  minutes	  resulted	  in	  exclusion	  from	  the	  study.	  Other	  conditions	  that	  resulted	  in	  exclusion	  from	  the	  study	  were	  pregnancy,	  possibility	  of	  pregnancy	  (based	  on	  recent	  unprotected	  sexual	  activity),	  diabetes,	  history	  of	  ascites,	  encephalopathy,	  esophageal	  variceal	  bleeding,	  hepatorenal	  syndrome,	  or	  non-­‐HCV	  liver	  disease.	  Individuals	  with	  a	  history	  of	  claustrophobia	  or	  metal	  exposure	  were	  excluded.	  Patients	  who	  have	  a	  confirmed	  HIV	  positive	  serostatus	  as	  determined	  using	  an	  HIV	  antibody	  test	  and	  confirmed	  with	  Western	  Blot	  analysis,	  are	  routinely	  referred	  to	  the	  ACTG	  clinic	  and	  are	  aware	  of	  their	  status	  before	  recruitment	  into	  the	  study.	  HCV	  status	  was	  confirmed	  using	  a	  HCV	  antibody	  test.	  As	  most	  of	  the	  patients	  are	  seen	  regularly	  at	  the	  clinic,	  HCV	  status	  was	  known	  for	  all	  participants.	  Markers	  of	  liver	  function	  were	  obtained	  through	  routine	  blood	  work	  within	  30	  days	  of	  their	  MRI	  and	  neuropsychological	  evaluation.	  	  
Study	  Visit:	  Upon	  recruitment	  patients	  were	  briefly	  screened	  to	  ensure	  inclusion	  criteria	  were	  met.	  The	  study	  visit	  included	  informed	  consent,	  	  a	  rapid	  urine	  sample	  to	  screen	  for	  current	  drug	  use,	  and	  completed	  a	  brief	  demographic	  questionnaire.	  Participants	  were	  then	  escorted	  to	  their	  one-­‐hour	  MRI	  appointment,	  followed	  by	  neuropsychological	  testing.	  	  
Neuropsychological	  evaluation-­‐	  Co-­‐infected	  group	  Neuropsychological	  measures	  were	  administered	  uniformly	  in	  the	  co-­‐infected	  group	  only.	  The	  majority	  of	  the	  HIV+	  group	  and	  HIV-­‐	  controls	  were	  administered	  minimal	  overlapping	  neuropsychological	  measures.	  	  The	  Repeatable	  Battery	  for	  the	  assessment	  of	  neuropsychological	  status	  (RBANS)	  has	  been	  used	  previously	  to	  study	  cognitive	  impairment	  associated	  with	  liver	  disease	  (Mooney	  et	  al.,	  2007)	  and	  demonstrated	  sensitivity	  to	  detection	  of	  a	  subcortical	  pattern	  of	  impairment	  commonly	  seen	  in	  liver	  disease.	  Cognitive	  impairment	  in	  HIV	  and	  Hepatitis	  C	  (mono	  and	  co-­‐infection)	  follows	  a	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subcortical	  pattern	  of	  impairment	  similar	  to	  that	  seen	  in	  liver	  disease.	  As	  such,	  the	  neuropsychological	  battery	  consisted	  primarily	  of	  subtests	  from	  the	  RBANS	  	  Simple	  Attention	  Digit	  Span	  from	  the	  RBANS	  was	  administered	  to	  assess	  attention.	  The	  Digit	  Span	  task	  requires	  individuals	  to	  repeat	  a	  series	  of	  numbers	  (starting	  with	  3	  numbers	  and	  progressing	  to	  9	  numbers)	  in	  the	  manner	  it	  was	  recited	  to	  them.	  Number	  correct	  was	  the	  outcome	  measure.	  Additionally,	  Symbol	  Search	  from	  the	  WAIS	  III	  was	  also	  administered.	  Symbol	  search	  requires	  individuals	  to	  scan	  rows	  containing	  five	  different	  symbols	  and	  two	  target	  symbols.	  For	  each	  row	  an	  individual	  must	  determine	  whether	  or	  not	  one	  of	  two	  target	  symbols	  are	  included	  in	  the	  five	  symbols	  grouped	  in	  each	  row	  and	  presented	  adjacent	  to	  the	  targets.	  Each	  person	  has	  two	  minutes	  to	  scan	  as	  many	  rows	  as	  quickly	  as	  they	  can	  and	  indicate	  “yes”	  the	  target	  is	  included	  or	  “no”	  the	  target	  is	  not	  present.	  Number	  of	  correct	  responses	  is	  the	  outcome	  variable.	  	  Psychomotor	  Speed	  Digit	  Symbol	  from	  the	  WAIS	  III,	  Trail	  Making	  A,	  and	  Grooved	  Pegboard-­‐-­‐dominant	  and	  non-­‐dominant	  hand	  provided	  measures	  of	  psychomotor	  speed.	  Digit	  Symbol	  presents	  numbers	  associated	  with	  symbols	  that	  participants	  must	  then	  copy	  the	  symbol	  under	  the	  numbers	  presented	  in	  a	  series	  of	  rows.	  The	  test	  takes	  90	  seconds.	  Trails	  A	  is	  a	  pen	  and	  paper	  task	  where	  individuals	  are	  required	  to	  connect	  a	  series	  of	  numbers	  starting	  at	  1	  and	  ending	  at	  25	  around	  a	  page.	  Grooved	  Pegboard	  consists	  of	  a	  board	  with	  25	  holes	  that	  have	  a	  squared	  and	  a	  rounded	  side	  and	  pegs	  that	  are	  designed	  to	  fit	  in	  the	  holes.	  The	  holes	  rotate	  in	  rows	  and	  the	  participant	  must	  use	  only	  one	  hand	  at	  a	  time	  to	  manipulate	  the	  peg	  so	  that	  it	  fits	  properly	  into	  the	  hole.	  The	  time	  to	  completion	  was	  the	  outcome	  measure	  for	  Trail	  Making	  A	  and	  Grooved	  Pegboard.	  Number	  correct	  was	  used	  as	  the	  outcome	  measure	  for	  Digit	  Symbol.	  Working	  memory/	  Executive	  Function	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  Executive	  function	  was	  assessed	  using	  Trail	  Making	  B,	  and	  Letter	  Number	  Sequencing	  (LN).	  An	  additional	  subtest,	  color-­‐word	  interference,	  from	  the	  Delis-­‐Kaplan	  Executive	  Function	  System	  (D-­‐KEFS)	  was	  administered	  to	  some	  of	  the	  subjects	  for	  secondary	  analyses.	  Trails	  B	  is	  a	  pen	  and	  paper	  measure	  that	  requires	  the	  participant	  to	  connect	  a	  series	  of	  numbers	  and	  letters	  in	  order	  around	  a	  page	  (e.g.	  1	  to	  A,	  2	  to	  B	  and	  so	  on).	  Letter-­‐Number	  Sequencing	  presents	  participants	  with	  a	  series	  of	  letters	  and	  numbers	  and	  they	  must	  order	  the	  numbers	  first	  in	  numerical	  order,	  then	  order	  the	  letters	  presented	  after	  the	  numbers	  in	  alphabetical	  order.	  Color-­‐Word	  Interference	  has	  three	  trials:	  	  1)	  blocks	  of	  color	  are	  presented	  and	  participants	  must	  name	  the	  colors	  across	  the	  rows	  presented	  as	  fast	  as	  they	  can	  without	  error.	  2)	  Color	  Words	  are	  presented	  in	  black	  ink	  and	  participants	  must	  read	  the	  words	  across	  the	  rows	  as	  fast	  as	  they	  can	  without	  errors,	  3)	  Color	  words	  are	  presented	  in	  an	  ink	  color	  that	  is	  incongruent	  with	  the	  color	  word	  (e.g.	  the	  word	  green	  typed	  in	  red	  ink).	  Participants	  must	  say	  the	  color	  of	  the	  ink,	  not	  read	  the	  word.	  The	  time	  to	  completion	  will	  be	  the	  outcome	  measure	  for	  Color-­‐Word	  Interference	  and	  Trails	  B.	  Number	  of	  appropriate	  words	  generated	  will	  be	  the	  outcome	  measure	  for	  Verbal	  Fluency	  and	  number	  correct	  for	  Letter-­‐Number	  sequencing.	  	  	  Memory	  Both	  Immediate	  and	  Delayed	  Memory	  was	  assessed	  with	  the	  RBANS.	  Immediate	  memory	  consists	  of	  List	  Learning	  and	  Story	  Memory.	  Delayed	  memory	  consists	  of	  List	  Recall,	  List	  Recognition,	  Story	  Recall	  and	  Figure	  Recall.	  List	  learning	  presented	  participants	  with	  10	  words,	  on	  four	  separate	  trials,	  each	  with	  immediate	  recall.	  For	  story	  memory,	  a	  story	  was	  presented	  to	  the	  subjects	  twice	  with	  an	  immediate	  recall	  after	  the	  presentation,	  followed	  by	  a	  free	  recall	  of	  the	  story	  approximately	  20	  minutes	  later.	  	  List	  recall	  is	  the	  free	  recall	  of	  the	  words	  learned	  in	  list	  learning	  approximately	  20	  minutes	  after	  presentation.	  List	  Recognition	  presented	  the	  participant	  with	  words	  that	  were	  learned	  in	  List	  recognition	  as	  well	  as	  items	  that	  were	  not	  on	  the	  list.	  	  Figure	  recall	  wass	  preceded	  by	  figure	  copy,	  where	  participants	  were	  required	  to	  copy	  a	  geometric	  figure,	  then	  
Heaps,	  Jodi,	  2012,	  UMSL,	  p.	  	  	  
	  
21	  
approximately	  20	  minutes	  after	  the	  figure	  is	  copied	  they	  were	  asked	  to	  recall	  the	  figure	  and	  draw	  it	  again.	  Semantic	  Fluency	  	   The	  fluency	  subtest	  from	  the	  RBANS	  was	  used	  to	  assess	  semantic	  fluency.	  Each	  participant	  was	  asked	  to	  name	  as	  many	  fruits	  or	  vegetables	  as	  they	  could	  think	  of	  in	  a	  one	  minute	  time	  frame.	  Number	  of	  responses	  was	  recorded	  and	  used	  as	  the	  outcome	  measure.	  Items	  that	  were	  repeated	  (perseverations)	  or	  did	  not	  match	  the	  semantic	  category	  (set-­‐loss	  error)	  were	  not	  included	  in	  the	  number	  of	  responses.	  
Quality	  of	  life/	  psychiatric	  questionnaires	  The	  Short	  Form-­‐36	  (SF-­‐36;(Ware	  &	  Sherbourne,	  1992))	  questionnaire	  was	  administered	  to	  measure	  health-­‐related	  quality	  of	  life,	  and	  the	  Fatigue	  Severity	  Scale	  (FSS;(Krupp,	  LaRocca,	  Muir-­‐Nash,	  &	  Steinberg,	  1989)	  was	  administered	  to	  assess	  physical	  fatigue.	  These	  scales	  	  were	  administered	  to	  determine	  if	  the	  mono	  and	  co-­‐infected	  groups	  differ	  significantly	  in	  terms	  of	  self-­‐reported	  feelings	  of	  health	  and	  fatigue.	  The	  Center	  for	  Epidemiological	  Scale	  for	  Depression	  (CES-­‐D)	  was	  used	  to	  assess	  current	  depression.	  This	  depression	  scale	  is	  commonly	  used	  in	  HIV	  research.	  	  Scores	  for	  each	  response	  were	  totaled	  (reverse	  scoring	  of	  items	  will	  be	  used	  where	  appropriate)	  and	  the	  total	  score	  provided	  the	  outcome	  measure.	  Patients	  also	  completed	  the	  Lawton	  and	  Brody	  Activities	  of	  Daily	  Living	  scale	  (ADL;	  (Lawton	  &	  Brody,	  1969)	  to	  determine	  the	  	  ability	  to	  complete	  both	  basic	  and	  instrumental	  ADLs.	  This	  scale	  has	  been	  found	  to	  detect	  functional	  impairments	  in	  the	  HIV-­‐mono	  and	  HIV/HCV-­‐co-­‐infected	  populations	  (Ryan	  et	  al.,	  2004).	  	  
Drug	  Use	  A	  detailed	  alcohol/drug	  use	  and	  dependence	  questionnaire	  was	  administered	  to	  determine	  illicit	  drug	  use	  and	  to	  determine	  if	  participants	  met	  DSM-­‐IV	  criteria	  for	  abuse	  or	  dependence.	  Additional	  information	  about	  the	  frequency,	  duration,	  and	  amount	  of	  each	  drug	  used	  was	  assessed	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using	  the	  Kreek-­‐McHugh-­‐Schluger-­‐Kellogg	  Scale	  (KMSK;	  (Kellogg	  et	  al.,	  2003).	  The	  KMSK	  allows	  for	  the	  quantification	  of	  drug	  use	  severity	  based	  on	  amount,	  duration,	  and	  frequency	  of	  use.	  	  The	  scale	  used	  for	  this	  study	  was	  modified	  to	  include	  marijuana	  use	  and	  has	  been	  used	  previously	  in	  NIH-­‐funded	  studies	  of	  HAND.	  As	  indicated	  previously	  a	  rapid	  urine	  screen	  was	  administered	  to	  assess	  recent	  drug	  use.	  Positive	  results	  were	  further	  examined	  by	  asking	  if	  use	  was	  prescription,	  or	  non-­‐prescription	  and	  time	  of	  most	  recent	  use.	  	  A	  positive	  result	  did	  not	  lead	  to	  exclusion	  because	  some	  drugs	  (e.g.,	  marijuana)	  may	  be	  detected	  for	  weeks	  after	  use.	  Additionally,	  some	  HIV	  therapies	  result	  in	  a	  positive	  test	  for	  marijuana.	  Therefore,	  the	  toxicology	  results	  were	  used	  to	  cross-­‐check	  the	  validity	  of	  self-­‐reported	  classes	  of	  drug	  use	  and	  current	  use.	  
Blood	  draws	  and	  hepatic	  tests	  Blood	  work	  was	  collected	  during	  routine	  clinic	  visits	  and	  took	  place	  within	  30	  days	  of	  MRI	  and	  neuropsychological	  testing.	  	  Liver	  function	  tests	  (LFT)	  were	  derived	  from	  a	  standard	  blood	  chemistry	  draw	  during	  a	  routine	  clinical	  visit.	  The	  main	  LFT	  variables	  used	  for	  this	  study	  was	  AST	  and	  platelets.	  CD4	  count	  and	  viral	  load	  (for	  HIV	  and	  HCV)	  was	  also	  recorded.	  
Determination	  of	  cirrhosis	  or	  fibrosis	  The	  ratio	  of	  AST	  to	  platelets	  (APRI)	  was	  calculated	  as	  the	  outcome	  variable	  for	  measuring	  hepatic	  function.	  This	  measure	  is	  a	  non-­‐invasive	  method	  to	  assess	  possible	  liver	  damage,	  and	  although	  less	  sensitive	  than	  liver	  biopsy,	  APRI	  has	  been	  shown	  to	  reliably	  predict	  fibrosis	  and	  cirrhosis	  (Carvalho-­‐Filho	  et	  al.,	  2008;	  Shaheen	  &	  Myers,	  2007;	  Tural	  et	  al.,	  2009).	  In	  addition,	  another	  non-­‐invasive	  measure	  of	  fibrosis,	  the	  FIB-­‐4	  was	  derived.	  The	  FIB-­‐4	  incorporates	  AST,	  ALT,	  age	  and	  platelet	  count	  to	  determine	  a	  degree	  of	  hepatic	  fibrosis	  (Trang,	  Petersen,	  &	  Snyder,	  2008;	  Tural	  et	  al.,	  2009).	  These	  data	  were	  used	  only	  for	  secondary	  analysis,	  as	  DTI	  indices	  represented	  the	  primary	  variables	  of	  interest	  in	  this	  study.	  	  
DTI	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Imaging	  was	  completed	  at	  Washington	  University	  Mallinckrodt	  Institute	  of	  Radiology.	  	  A	  Siemens	  3T	  Tim	  Trio	  was	  used	  for	  scans	  completed	  by	  the	  HIV+	  and	  HIV/HCV+	  group.	  Approximately	  half	  of	  the	  controls	  and	  two	  of	  the	  HIV/HCV	  co-­‐infected	  individuals	  were	  scanned	  using	  a	  Siemens	  3T	  Allegra.	  A	  T1-­‐weighted	  three-­‐dimensional	  magnetization-­‐prepared	  rapid	  acquisition	  gradient	  echo	  (MPRAGE)	  sequence	  (Time	  of	  repetition	  (TR)	  /inversion	  time	  (TI)/	  echo	  time	  (TE)	  =	  2400/1000/3.16	  ms,	  flip	  angle	  =	  8°,	  and	  voxel	  size	  =	  1	  ×	  1	  ×	  1	  mm3)	  was	  obtained.	  A	  T2-­‐weighted	  fast	  spin	  echo	  (T2W	  FSE)	  scan	  (TR	  =	  4380	  ms,	  TE	  =	  94	  ms,	  1	  ×	  1×	  3	  mm)	  was	  also	  acquired.	  Images	  were	  visually	  inspected	  at	  the	  time	  of	  scanning	  and	  an	  additional	  scan	  was	  performed	  if	  significant	  motion	  artifacts	  were	  observed.	  Two	  acquisitions	  of	  diffusion-­‐weighted	  images	  were	  collected	  for	  the	  assessment	  of	  white	  matter	  microstructural	  integrity	  (2	  x	  2	  x	  2	  mm	  voxels,	  TR=9,900	  ms,	  TE=102	  ms,	  flip	  angle	  =90o,	  23	  directions	  with	  b-­‐values	  between	  0	  and	  1400	  s/mm2).	  	  
DTI	  Registration	  
A	  detailed	  review	  of	  the	  registration	  methods	  has	  been	  previously	  described	  (Shimony,	  Burton,	  Epstein,	  McLaren,	  Sun,	  Snyder,	  2006).	  In	  brief,	  affine	  transforms	  computed	  by	  image	  registration	  were	  used	  to	  define	  the	  spatial	  relationships	  between	  all	  images.	  Multi-­‐modal	  image	  registration	  between	  the	  anatomical	  images	  (T2W	  FSE	  and	  T1W	  MPRAGE)	  was	  accomplished	  using	  vector	  gradient	  measure	  (VGM)	  maximization	  (Rowland,	  Garbow,	  Laforest,	  Snyder,	  2005).	  The	  first	  DTI	  volume	  (I0,	  with	  b	  =	  0)	  was	  registered	  to	  the	  T2W	  FSE	  image,	  which	  was	  then	  registered	  to	  the	  T1W	  MPRAGE	  image.	  	  Subsequently	  the	  image	  was	  registered	  to	  an	  atlas	  that	  conformed	  to	  the	  Tailairach	  system	  (Lancaster,	  Glass,	  Lankipalli,	  Downs,	  Mayberg,	  and	  Fox,	  1995;	  Talairach	  and	  Tournoux,	  1988).	  
DTI	  Motion	  Correction	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The	  DTI	  dataset	  was	  motion-­‐corrected	  by	  first	  aligning	  each	  DTI	  volume	  to	  the	  geometric	  mean	  volume	  of	  each	  group	  of	  images	  that	  shared	  similar	  degrees	  of	  diffusion	  sensitization.	  The	  geometric	  mean	  volume	  was	  then	  recomputed	  before	  aligning	  to	  the	  first	  acquired	  I0	  image.	  Next,	  transforms	  between	  the	  different	  images	  were	  algebraically	  composed.	  Repeating	  these	  steps	  three	  times	  yielded	  realignments	  with	  errors	  that	  had	  an	  estimated	  internal	  consistency	  <	  0.1	  mm.	  All	  transforms	  were	  9	  parameter	  affine	  (rigid	  body	  +	  scanner	  axis	  stretch)	  computed	  by	  VGM	  maximization	  (Rowland	  et	  al,	  2005).	  Conventional	  intensity	  correlation	  maximization	  was	  used	  to	  align	  the	  I0	  volumes	  of	  each	  DTI	  dataset.	  The	  final	  motion-­‐corrected	  results	  were	  obtained	  by	  algebraically	  composing	  all	  transforms	  and	  averaging	  datasets	  after	  application	  of	  the	  composed	  transforms	  using	  cubic	  spline	  interpolation.	  	  
DTI	  Computations	  
DTI	  post-­‐processing	  was	  performed	  using	  previously	  described	  methods	  (Shimony	  et	  al.,	  2009).	  Briefly,	  the	  diffusion	  tensor	  and	  the	  3	  eigenvalues	  were	  calculated	  using	  log-­‐linear	  regression	  in	  each	  voxel.	  Using	  standard	  methods	  (Basser,	  Mattiello,	  LeBihan,	  1994),	  the	  three	  eigenvalues	  were	  used	  to	  calculate	  RD,	  AD,	  and	  MD.	  Anisotropy	  was	  expressed	  as	  FA,	  which	  is	  normalized	  to	  assume	  a	  range	  from	  0	  to	  1.	  Diffusion	  parameters	  were	  measured	  and	  sampled	  for	  each	  individual	  by	  averaging	  particular	  regions	  of	  interest	  within	  the	  corpus	  callosum	  (CC)	  and	  frontal	  forceps.	  
Despite	  motion	  correction,	  in	  the	  HIV/HCV+	  group	  DTI	  data	  were	  compromised	  due	  to	  registration	  errors,	  and	  eddy	  distortions	  in	  the	  frontal	  lobe	  that	  rendered	  some	  images	  unusable	  for	  ROI	  analysis.	  In	  addition,	  DTI	  metrics	  were	  highly	  abnormal	  (>4SD	  from	  the	  mean	  of	  the	  entire	  group)	  for	  two	  cases	  in	  the	  HIV+	  group	  and	  one	  case	  in	  the	  HIV/HCV+	  group	  and	  as	  such	  were	  not	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included	  in	  analyses.	  As	  a	  result	  the	  final	  numbers	  for	  the	  neuroimaging	  analysis	  were	  HIV+	  n=23,	  HIV/HCV+	  n=21,	  and	  controls	  n=25.	  
Region	  of	  Interest	  Analysis	  
DTI	  parameters	  were	  obtained	  for	  the	  CC	  and	  frontal	  forceps	  using	  manually-­‐drawn	  regions	  of	  interest	  (ROI)	  created	  in	  Analyze	  v.	  11.0	  (Mayo	  Clinic,	  Rochester,	  MN;	  Figure	  1).	  ROIs	  for	  both	  regions	  were	  manually	  delineated	  using	  the	  threshold	  option	  (FA=	  0.3)	  with	  adjustments	  where	  needed.	  The	  threshold	  of	  FA	  equal	  to	  or	  greater	  than	  0.3	  was	  set	  based	  on	  parameters	  used	  in	  previous	  studies	  of	  HIV	  and	  DTI	  (Gongvatana,	  2010;	  Wright	  2012).	  Additionally,	  the	  threshold	  of	  0.3	  provides	  confidence	  that	  the	  voxels	  selected	  are	  primarily	  white	  matter	  volumes	  rather	  than	  voxels	  consisting	  of	  partial	  gray/partial	  white	  matter.	  	  The	  genu,	  body,	  and	  splenium	  of	  the	  CC	  were	  drawn	  on	  the	  mid-­‐sagittal	  slice	  of	  each	  subject’s	  FA	  map	  as	  seen	  in	  Figure	  1.	  Each	  region	  was	  sampled	  across	  five	  slices	  that	  were	  centered	  upon	  this	  slice.	  DTI	  parameters	  were	  calculated	  based	  on	  the	  mean	  of	  the	  five	  slices.	  Additionally,	  the	  CC	  was	  segmented	  into	  five	  sections	  based	  on	  anatomical	  connections	  to	  cortical	  areas	  as	  described	  in	  Rosas	  et	  al.	  (2010).	  These	  sections	  are	  as	  follows:	  CC1-­‐prefrontal,	  CC2-­‐	  premotor	  and	  supplementary	  motor,	  CC3/CC4-­‐sensory	  motor,	  CC5-­‐	  parietal,	  temporal,	  occipital.	  	  	  ROIs	  for	  the	  frontal	  forceps	  were	  also	  drawn	  using	  the	  threshold	  option	  in	  Analyze	  and	  manual	  adjustments	  when	  needed.	  ROIs	  were	  drawn	  in	  atlas	  space	  and	  were	  sampled	  from	  five	  axial	  slices	  as	  shown	  in	  Figure	  2.	  
Statistical	  Analysis	  Descriptive	  analyses	  were	  carried	  out	  prior	  to	  the	  analyses	  of	  the	  aims	  to	  characterize	  the	  groups.	  Age,	  education,	  and	  drug	  use	  were	  analyzed	  between	  groups	  using	  ANOVA..	  An	  independent	  measures	  t-­‐test	  was	  used	  to	  compare	  the	  HIV+	  and	  HIV/HCV+	  groups	  on	  clinical	  markers	  such	  as	  CD4	  count,	  nadir	  CD4	  count,	  plasma	  VL,	  time	  since	  diagnosis	  of	  HIV+	  infection,	  and	  APRI.	  
Aim	  1	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The	  purpose	  of	  aim	  1	  was	  to	  identify	  microstructural	  alterations	  in	  the	  brain	  associated	  with	  co-­‐infection	  using	  DTI.	  I	  hypothesized	  that	  co-­‐infected	  individuals	  would	  exhibit	  significantly	  decreased	  FA	  and	  increased	  MD,	  AD	  and	  RD	  in	  white	  matter	  in	  two	  regions	  of	  interest.	  The	  frontal	  forceps	  and	  the	  corpus	  callosum	  compared	  to	  HIV	  mono-­‐infected	  individuals	  and	  controls.	  Using	  separate	  ANOVAs	  for	  each	  of	  the	  dependent	  DTI	  measures,	  a	  main	  effect	  of	  group	  status	  on	  frontal	  white	  and	  corpus	  callosum	  DTI	  indices	  (FA,	  MD,	  AD,	  and	  RD)	  values	  were	  examined.	  A	  Hochberg	  G2	  post-­‐hoc	  test	  was	  used	  to	  determine	  where	  the	  group	  differences	  occur	  (Hochberg	  and	  Tamhane,	  1987).	  	  
Aim	  2	   	   The	  second	  aim	  of	  the	  study	  was	  to	  identify	  neurological	  and	  neurobehavioral	  predictors	  of	  cognitive	  performance	  among	  co-­‐infected	  with	  HIV/HCV.	  	  Data	  were	  analyzed	  using	  a	  regression	  model	  within	  the	  co-­‐infected	  group	  to	  determine	  factors	  that	  are	  most	  predictive	  of	  cognitive	  deficits.	  Deficits	  were	  determined	  by	  group	  mean	  scores	  within	  cognitive	  domains	  such	  as	  memory,	  learning,	  psychomotor	  speed	  and	  executive	  function.	  A	  z-­‐score	  for	  each	  measure	  was	  calculated	  based	  on	  current	  normative	  scores	  adjusted	  for	  age,	  education,	  and	  gender.	  These	  z-­‐scores	  were	  then	  summed	  and	  averaged	  to	  create	  a	  sum	  z-­‐score	  for	  each	  domain	  that	  were	  further	  summed	  across	  domains	  to	  determine	  a	  global	  measure	  of	  cognitive	  function.	  Independent	  factors	  included	  DTI	  indices,	  substance	  use	  (summed	  across	  different	  drugs	  of	  abuse),	  liver	  function,	  and	  self-­‐	  reported	  physical/mental	  health	  (from	  SF-­‐36).	  	  Neuropsychological	  measures	  were	  administered	  uniformly	  in	  the	  co-­‐infected	  group	  only,	  therefore	  all	  analyses	  of	  cognitive	  functioning	  were	  for	  the	  co-­‐infected	  group	  only.	  
Results	  Analysis	  of	  demographic	  and	  drug	  use	  variables	   	  	   Preliminary	  analyses	  of	  demographic	  and	  drug	  use	  information	  are	  presented	  in	  Table	  1.	  There	  were	  no	  significant	  group	  differences	  in	  age	  or	  education	  between	  the	  three	  groups	  although	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the	  control	  group	  did	  have	  a	  slightly	  higher	  level	  of	  education.	  Additionally,	  the	  control	  group	  scored	  significantly	  higher	  on	  the	  WRAT-­‐3,	  a	  measure	  of	  reading	  ability	  compared	  to	  both	  the	  HIV+	  and	  HIV/HCV+	  groups.	  	  	   The	  KMSK	  was	  administered	  to	  quantify	  drug	  use	  (see	  Table	  2).	  For	  the	  individuals	  who	  provided	  responses	  on	  this	  measure	  there	  were	  no	  significant	  differences	  in	  terms	  of	  alcohol	  and	  tobacco	  use	  between	  the	  groups;	  however,	  for	  the	  most	  part	  the	  HIV+	  and	  HIV/HCV+	  groups	  reported	  current	  tobacco	  use,	  whereas	  many	  of	  the	  controls	  had	  a	  past	  history	  of	  drug	  use,	  but	  did	  not	  report	  current	  use	  of	  tobacco.	  Cocaine	  use	  was	  significantly	  higher	  in	  the	  infected	  groups	  compared	  to	  controls,	  but	  did	  not	  differ	  significantly	  between	  the	  HIV+	  and	  HIV/HCV+	  groups.	  Marijuana	  use	  was	  significantly	  different	  between	  all	  of	  the	  groups	  with	  the	  HIV+	  mono-­‐infected	  group	  having	  the	  highest	  scores	  on	  the	  KMSK	  and	  the	  controls	  having	  the	  lowest	  scores.	  	  	   The	  HIV+	  and	  HIV/HCV+	  groups	  were	  similar	  in	  terms	  of	  current	  and	  nadir	  CD4	  counts	  and	  HIV	  viral	  load.	  There	  was	  a	  significant	  difference	  between	  the	  groups	  in	  terms	  of	  time	  since	  HIV	  diagnosis	  with	  the	  HIV/HCV+	  group	  having	  been	  infected	  on	  average	  14	  years	  with	  HIV,	  and	  the	  HIV+	  group	  having	  been	  infected	  an	  average	  of	  9	  years	  with	  HIV	  (p=0.032,	  see	  Fig	  8).	  	  	  DTI-­‐	  CC	  	   There	  was	  a	  significant	  effect	  of	  group	  status	  on	  FA	  in	  the	  CC,	  with	  controls	  having	  significantly	  higher	  FA	  than	  both	  the	  HIV+	  (p=0.007)	  and	  the	  HIV/HCV	  groups	  (p=0.001).	  The	  HIV+	  group	  did	  have	  slightly	  higher	  FA	  values	  than	  the	  HIV/HCV	  group,	  however	  the	  difference	  was	  not	  significant.	  There	  was	  no	  difference	  between	  the	  groups	  in	  terms	  of	  AD,	  however	  there	  was	  a	  trend	  for	  lower	  MD	  in	  the	  control	  group	  compared	  to	  the	  infected	  groups.	  Additionally,	  there	  was	  a	  significant	  difference	  between	  controls	  and	  the	  HIV/HCV	  group	  on	  RD	  (p=0.019)	  but	  only	  a	  trend	  for	  increased	  RD	  between	  the	  HIV+	  group	  and	  controls	  (p=0.055,	  see	  Fig.	  1).	  	  	   In	  order	  to	  determine	  a	  regional	  effect	  of	  the	  differences	  in	  the	  CC,	  this	  ROI	  was	  segmented	  into	  five	  sections,	  based	  on	  the	  anatomical	  connections	  into	  frontal,	  parietal,	  and	  occipital	  regions.	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Since	  FA	  and	  RD	  were	  significantly	  different	  between	  the	  control	  and	  infected	  groups,	  a	  MANOVA	  was	  conducted	  for	  each	  of	  the	  5	  sections	  of	  the	  CC	  in	  order	  to	  identify	  group	  differences	  in	  specific	  regions	  of	  the	  CC.	  There	  was	  a	  significant	  difference	  between	  the	  co-­‐infected	  groups	  and	  the	  controls	  in	  terms	  of	  RD	  in	  the	  anterior	  two-­‐fifths	  and	  the	  central	  region	  of	  the	  CC	  with	  the	  co-­‐infected	  group	  having	  higher	  RD	  than	  the	  controls	  (see	  Figs.2-­‐6).	  	  	   An	  additional	  analysis	  was	  conducted	  applying	  the	  same	  threshold	  of	  .3	  to	  the	  CC.	  The	  control	  group	  had	  significantly	  more	  area	  in	  the	  CC	  compared	  to	  both	  the	  HIV+	  (p=	  0.014)	  and	  HIV/HCV	  groups	  (p<0.001),	  with	  the	  HIV/HCV	  having	  the	  smallest	  ROI	  sampled	  within	  the	  threshold	  limits.	  	  DTI-­‐	  frontal	  horns	  	   There	  were	  no	  significant	  differences	  between	  the	  groups	  on	  any	  of	  the	  DTI	  metrics	  in	  the	  frontal	  area;	  however,	  when	  assessing	  the	  area	  selected	  (based	  on	  the	  threshold	  of	  FA	  greater	  or	  equal	  to	  0.3)	  the	  HIV/HCV	  group	  had	  significantly	  less	  white	  matter	  in	  the	  frontal	  forceps	  that	  fell	  within	  the	  threshold	  limits	  compared	  to	  controls	  resulting	  in	  smaller	  frontal	  ROIs	  for	  the	  HIV/HCV+	  group	  compared	  to	  controls.	  The	  HIV+	  group	  also	  had	  a	  smaller	  area	  of	  white	  matter	  voxels	  within	  the	  threshold	  limits;	  however,	  the	  difference	  in	  white	  matter	  area	  was	  not	  significantly	  lower	  between	  the	  HIV+	  group	  and	  controls,	  or	  significantly	  higher	  than	  the	  HIV/HCV	  group.	  This	  is	  of	  note	  as	  the	  ROIs	  were	  drawn	  based	  on	  the	  individual	  anatomy	  of	  each	  participant	  using	  a	  marker	  (FA)	  of	  white	  matter	  integrity.	  As	  white	  matter	  integrity	  is	  compromised	  the	  value	  of	  FA	  can	  decrease	  to	  levels	  below	  the	  applied	  threshold.	  Correlational	  analyses	  	   Correlational	  analyses	  did	  not	  reveal	  any	  relationship	  between	  the	  individual	  scores	  on	  the	  KMSK	  and	  any	  of	  the	  DTI	  measures.	  There	  was	  a	  moderate	  relationship	  between	  depression	  symptomatology,	  MD	  and	  RD	  values	  in	  the	  corpus	  callosum	  for	  the	  co-­‐infected	  group	  (Fig.	  7).	  	  The	  measure	  of	  depression	  symptoms,	  the	  CES-­‐D,	  was	  only	  collected	  from	  15	  of	  the	  23	  individuals	  in	  the	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HIV+	  mono-­‐infected	  group,	  but	  there	  was	  no	  relationship	  between	  depression	  symptoms	  and	  DTI	  variables	  in	  the	  HIV+	  mono-­‐infected	  group.	  Regression	  analysis-­‐	  A	  regression	  model	  including	  substance	  use	  scores	  (KMSK),	  liver	  status	  (APRI),	  self-­‐reported	  physical	  and	  mental	  health	  scores	  (SF-­‐36),	  and	  DTI	  indices	  was	  completed	  to	  determine	  theI	  ndividual	  and	  combined	  effects	  of	  these	  variables	  on	  neurocognitive	  function.	  This	  analysis	  was	  conducted	  for	  the	  co-­‐infection	  group	  only.	  DTI	  indices	  included	  in	  the	  analysis	  were	  the	  variables	  that	  significantly	  differed	  from	  the	  control	  groups	  (FA	  and	  RD	  in	  frontal	  and	  CC	  white	  matter).	  The	  overall	  regression	  model	  did	  not	  identify	  significant	  associations	  between	  these	  variables	  and	  peformance	  performance	  for	  any	  of	  the	  cognitive	  domains,	  or	  global	  cognition.	  Additionally,	  none	  of	  the	  individual	  variables	  were	  significantly	  associated	  with	  cognitive	  performance	  in	  the	  co-­‐infected	  group;	  however,	  in	  the	  domain	  of	  working	  memory/executive	  function	  there	  was	  a	  trend	  for	  CC	  RD	  to	  relate	  to	  performance	  on	  these	  tasks	  (p=0.078,	  see	  Fig.	  9).	  Discussion	  	   This	  study	  identifies	  an	  additional	  impact	  of	  HIV/HCV	  co-­‐infection	  on	  white	  matter	  structural	  integrity.	  In	  general,	  the	  co-­‐infected	  group	  had	  the	  lowest	  FA,	  and	  the	  highest	  values	  for	  MD,	  AD	  and	  RD	  of	  the	  groups,	  however	  only	  FA	  and	  RD	  were	  significantly	  different	  in	  the	  co-­‐infected	  group	  compared	  to	  the	  controls	  in	  the	  anterior	  regions	  of	  the	  CC.	  The	  reductions	  seen	  in	  FA	  and	  increases	  in	  RD	  primarily	  in	  the	  anterior	  areas	  of	  the	  brain	  indicate	  that	  the	  integrity	  of	  myelin	  is	  compromised	  in	  co-­‐infection	  (Avram,	  Guidon,	  and	  Song,	  2010),	  particularly	  in	  the	  anterior	  regions	  of	  the	  brain.	  This	  is	  effect	  is	  greater	  than	  the	  effect	  of	  HIV	  mono-­‐infection,	  as	  demonstrated	  by	  the	  lack	  of	  significant	  differences	  between	  the	  HIV+	  and	  control	  groups.	  Prior	  studies	  have	  associated	  co-­‐infection	  with	  lower	  FA	  and	  MD	  in	  various	  brain	  regions	  (Gongvatana	  et	  al.,	  2011)	  and	  increased	  MD	  in	  a	  whole	  brain	  analysis	  (Stebbins	  et	  al.,	  2007)	  compared	  to	  HIV+	  mono-­‐infected	  individuals.	  	  These	  previous	  studies	  did	  not	  examine	  the	  indices	  of	  AD	  and	  RD,	  nor	  did	  they	  compare	  HIV/HCV+	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groups	  to	  controls.	  On	  the	  contrary,	  this	  study	  focused	  on	  the	  CC	  and	  frontal	  forceps,	  and	  did	  not	  measure	  DTI	  metrics	  in	  other	  white	  matter	  fiber	  tracts.	  The	  primary	  reason	  for	  the	  selection	  of	  the	  CC	  is	  the	  high	  directionality	  of	  fibers,	  providing	  a	  good	  measure	  of	  overall	  white	  matter	  integrity	  (Wright	  et	  al.,	  2012).	  Additionally,	  the	  CC	  connects	  with	  cortical	  regions	  in	  an	  organized	  manner	  that	  are	  related	  to	  specific	  cognitive	  functions	  (Rosas	  et	  al.,	  2010).	  	  This	  provided	  an	  ideal	  means	  of	  assessing	  white	  matter	  integrity	  and	  cognitive	  function.	  	   One	  potential	  explanation	  for	  the	  greater	  effect	  of	  co-­‐infection	  that	  has	  been	  raised	  previously	  is	  liver	  dysfunction	  in	  the	  HIV/HCV	  groups.	  A	  proposed	  theoretical	  model	  defines	  liver	  dysfunction	  as	  the	  mechanism	  for	  	  the	  release	  of	  pro-­‐inflammatory	  cytokines	  and	  astrocytic	  swelling	  that	  can	  progress	  to	  hepatic	  encephalopathy	  (Haussinger	  and	  Schliess,	  2008).	  However,	  HCV	  has	  been	  found	  in	  brain	  tissue	  of	  autopsy	  patients	  (Vargas	  et	  al.,	  2002).	  This	  finding	  provides	  an	  alternate	  mechanism,	  whereby	  the	  presence	  of	  HCV	  in	  the	  brain	  leads	  to	  an	  upregulated	  immune	  response	  (Letendre	  et	  al.,	  2007).	  There	  are	  no	  studies	  reporting	  any	  direct	  infection	  of	  neurons	  by	  HCV.	  In	  this	  study	  the	  APRI	  score,	  an	  index	  of	  cirrhosis	  and	  fibrosis,	  was	  significantly	  higher	  in	  the	  co-­‐infected	  group	  than	  the	  mono-­‐infected	  group,	  though	  neither	  group	  had	  APRI	  or	  FIB-­‐4	  values	  suggestive	  of	  	  advanced	  liver	  disease	  (Shaheen	  and	  Myers,	  2007).	  In	  fact,	  none	  of	  the	  participants	  in	  the	  study	  had	  scores	  indicative	  of	  cirrhosis	  or	  fibrosis.	  	  	   The	  alterations	  in	  DTI	  metrics	  in	  the	  co-­‐infected	  group	  further	  extends	  prior	  studies	  indicating	  that	  cognitive	  changes,	  and	  neuroimaging	  abnormalities	  exist	  in	  individuals	  who	  have	  not	  progressed	  to	  the	  later	  stages	  of	  liver	  disease	  (Hinkin,	  et	  al	  2008;	  Ryan	  et	  al.,	  2004;	  Weissenborn	  et	  al,	  2004).	  The	  results	  of	  this	  study	  do	  not	  provide	  information	  about	  the	  white	  matter	  structural	  integrity	  in	  those	  individuals	  who	  have	  developed	  cirrhosis	  or	  fibrosis.	  Future	  neuroimaging	  work	  should	  compare	  HIV/HCV	  individuals	  with	  normal	  liver	  function	  to	  individuals	  with	  compromised	  liver	  function.	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   Another	  potential	  explanation	  for	  the	  alterations	  in	  DTI	  metrics	  in	  the	  co-­‐infected	  group	  that	  has	  been	  raised	  previously	  is	  recreational	  drug	  use	  (see	  Letendre	  and	  Paul	  publication).	  In	  the	  present	  study	  the	  co-­‐infected	  group	  had	  significantly	  higher	  self-­‐reported	  use	  of	  recreational	  drugs,	  especially	  cocaine	  and	  marijuana	  compared	  to	  the	  controls.	  However,	  there	  was	  no	  difference	  between	  the	  mono-­‐infected	  group	  and	  the	  co-­‐infected	  group	  in	  terms	  of	  drug	  use,	  and	  the	  correlational	  analysis	  did	  not	  reveal	  associations	  between	  the	  scores	  on	  the	  KMSK	  and	  any	  of	  the	  DTI	  metrics.	  Drug	  use	  histories	  were	  recorded	  from	  self-­‐report	  measures	  and	  require	  participants	  to	  recall	  information	  about	  drug	  use	  that	  occurred	  primarily	  in	  the	  past.	  It	  is	  possible	  that	  the	  participants	  did	  not	  accurately	  recall	  their	  drug	  use,	  although	  this	  would	  be	  likely	  to	  occur	  in	  both	  patient	  groups.	  Of	  note,	  the	  KMSK	  did	  not	  account	  for	  all	  possible	  types	  of	  drug	  use	  and	  therefore	  drug	  use	  cannot	  be	  entirely	  ruled	  out	  as	  a	  potential	  mechanism	  of	  the	  alterations	  in	  white	  matter	  evident	  in	  the	  HIV/HCV+	  group.	  	  	   Both	  the	  co-­‐infected	  and	  mono-­‐infected	  groups	  were	  similar	  in	  terms	  of	  their	  current	  clinical	  profiles,	  with	  similar	  current	  CD4	  levels	  and	  low	  or	  undetectable	  viral	  loads	  in	  the	  majority	  of	  individuals,	  with	  a	  couple	  of	  outliers	  in	  each	  group.	  Interestingly,	  neither	  age,	  education,	  nor	  time	  since	  diagnosis	  correlated	  with	  any	  of	  the	  imaging	  markers	  in	  any	  of	  the	  groups.	  	  Both	  groups	  also	  had	  similar	  nadir	  CD4	  counts.	  Correlational	  analyses	  controlling	  for	  age	  revealed	  a	  moderate	  relationship	  between	  nadir	  CD4	  and	  MD	  (r=-­‐.56,	  p=.01)	  and	  RD	  (r=-­‐.47,	  p=.04)	  values	  in	  the	  CC	  in	  the	  HIV+	  group;	  however	  this	  relationship	  is	  not	  evident	  in	  the	  HIV/HCV+	  group	  (See	  Fig.XX).	  Since	  both	  the	  HIV+	  group	  and	  HIV/HCV+	  group	  had	  similar	  nadir	  CD4	  levels	  the	  lack	  of	  correlation	  between	  this	  variable	  and	  the	  imaging	  markers	  indicates	  that	  the	  alterations	  in	  white	  matter	  in	  the	  HIV/HCV+	  group	  may	  be	  affected	  by	  different	  factors.	  	  	   In	  the	  HIV/HCV+	  group	  there	  was	  a	  moderate	  correlation	  between	  depression	  indices	  and	  both	  MD	  and	  RD	  in	  the	  CC.	  	  	  Although	  this	  correlation	  was	  not	  similarly	  observed	  in	  the	  HIV+	  group	  only	  half	  of	  the	  HIV+	  group	  provided	  information	  about	  their	  depressive	  symptomatology.	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Depression	  has	  been	  previously	  linked	  to	  both	  volumetric	  and	  white	  matter	  alterations	  outside	  of	  HIV,	  and	  is	  a	  common	  comorbidity	  in	  HIV	  and	  HCV.	  A	  number	  of	  studies	  have	  linked	  inflammation	  to	  depression.	  For	  example,	  medical	  conditions	  associated	  with	  inflammation	  or	  immune	  dysfunction	  have	  a	  higher	  prevalence	  of	  depression	  (for	  review	  see:	  Hannestad,	  2008),	  and	  when	  anti-­‐inflammatory	  agents	  are	  initiated	  many	  patients	  report	  a	  decrease	  in	  depressive	  symptomatology.	  A	  number	  of	  studies	  have	  also	  shown	  an	  increase	  in	  pro-­‐inflammatory	  cytokines	  in	  depression,	  although	  this	  is	  not	  a	  consistent	  finding	  across	  studies	  (Hannestad,	  2008)	  Considering	  the	  mechanism	  for	  altered	  microstructural	  integrity	  in	  HIV	  and	  co-­‐infection	  is	  believed	  to	  be	  the	  result	  of	  damage	  from	  pro-­‐inflammatory	  cytokines	  it	  is	  possible	  the	  higher	  levels	  of	  depression	  symptomatology	  in	  this	  cohort	  may	  be	  due	  to	  an	  increase	  in	  inflammatory	  agents	  in	  the	  brain	  due	  to	  HIV	  and	  HCV	  that	  are	  affecting	  white	  matter	  integrity.	  	  	  	   It	  is	  possible	  that	  the	  presence	  of	  HCV	  itself	  results	  in	  a	  greater	  change	  in	  the	  white	  matter	  of	  the	  co-­‐infected	  subjects.	  Studies	  have	  shown	  that	  HCV	  is	  present	  in	  the	  CNS	  and	  may	  replicate	  in	  the	  CNS	  of	  HIV/HCV	  co-­‐infected	  patients	  (Forton	  2004,	  Letendre,	  2007,	  Morgello,	  2005),	  especially	  among	  individuals	  with	  detectible	  HIV	  viral	  loads	  in	  the	  CSF.	  At	  least	  one	  study	  has	  shown	  that	  microglia	  and	  astrocytes	  can	  be	  infected	  by	  HCV	  (Wilkinson,	  2009).	  HCV	  is	  associated	  with	  an	  up-­‐regulation	  of	  pro-­‐inflammatory	  cytokines	  that	  have	  been	  shown	  to	  affect	  white	  matter	  (Letendre;	  others).	  This	  has	  been	  evidenced	  in	  a	  number	  of	  immune-­‐mediated	  diseases	  such	  that	  higher	  levels	  of	  central	  and	  peripheral	  cytokines	  and	  chemokines	  result	  in	  white	  matter	  demylination.	  	  Using	  H-­‐MRS,	  co-­‐infection	  with	  HIV/HCV	  is	  associated	  with	  markers	  of	  decreased	  mI	  and	  increased	  choline,	  markers	  of	  microglial	  functioning	  and	  inflammation	  respectively.	  Using	  DTI,	  the	  alterations	  specific	  to	  FA	  and	  RD	  indicate	  that	  the	  integrity	  of	  myelin	  is	  affected	  in	  HIV/HCV	  co-­‐infection.	  In	  other	  HIV	  neuroimaging	  studies,	  when	  HCV	  co-­‐infection	  is	  entered	  as	  a	  variable	  of	  interest	  it	  has	  consistently	  been	  associated	  with	  an	  increased	  risk	  for	  white	  matter	  alterations	  (Gongvatana,	  2010)	  and	  neuropsychological	  deficits	  (Wright,	  2012).	  	  The	  result	  of	  this	  study	  show	  that	  although	  the	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difference	  in	  white	  matter	  microstructural	  integrity	  between	  the	  mono-­‐	  and	  co-­‐infected	  groups	  is	  not	  significantly	  different,	  co-­‐infected	  individuals	  are	  more	  likely	  to	  have	  alterations	  in	  the	  white	  matter	  when	  compared	  to	  seronegative	  individuals.	  	   Although	  there	  was	  no	  	  significant	  relationship	  between	  the	  selected	  DTI	  metrics	  and	  neuropsychological	  domains	  there	  was	  a	  trend	  for	  RD	  in	  the	  anterior	  CC	  to	  predict	  performance	  in	  executive	  functioning/working	  memory	  and	  psychomotor	  speed	  measures.	  The	  sample	  was	  relatively	  small,	  which	  may	  have	  reduced	  power	  to	  detect	  a	  significant	  relationship	  between	  the	  DTI	  metrics	  and	  neuropsychological	  measures.	  	  Still	  this	  finding	  is	  important,	  as	  previous	  studies	  of	  co-­‐infection	  and	  DTI	  have	  not	  specifically	  assessed	  the	  relationship	  between	  areas	  of	  altered	  DTI	  metrics	  and	  cognitive	  performance.	  	  The	  use	  of	  archival	  data	  limited	  the	  complete	  assessment	  of	  neuropsychological	  domains	  across	  the	  groups.	  Although	  all	  individuals	  included	  in	  the	  study	  received	  some	  neuropsychological	  testing	  the	  battery	  was	  not	  standardized	  across	  the	  three	  groups.	  However,	  the	  HIV/HCV	  group	  received	  a	  uniform	  set	  of	  measures	  allowing	  the	  assessment	  of	  cognition	  in	  this	  group	  and	  the	  ability	  to	  determine	  the	  relationship	  between	  specific	  cognitive	  domains	  and	  DTI	  metrics.	  The	  use	  of	  z-­‐scores	  to	  determine	  the	  contribution	  of	  DTI,	  substance	  use,	  and	  liver	  function	  on	  neuropsychological	  domains	  provided	  a	  measure	  of	  how	  this	  group	  performed	  compared	  to	  a	  normative	  population.	  As	  seen	  in	  Table	  3	  the	  co-­‐infected	  group	  performed	  below	  the	  normative	  mean	  (as	  indicated	  by	  –z	  scores)	  on	  almost	  all	  of	  the	  measures.	  	  	   All	  of	  the	  HIV/HCV+	  participants	  in	  the	  study	  were	  treated	  for	  HIV,	  but	  untreated	  for	  HCV.	  Use	  of	  HCV	  therapies	  is	  commonly	  associated	  with	  fatigue,	  flu-­‐like	  symptoms,	  depression,	  anxiety,	  and	  sleep	  disturbances.	  These	  symptomscan	  affect	  the	  validity	  of	  neuropsycological	  testing.	  Recently	  there	  have	  been	  advances	  in	  the	  treatment	  of	  HCV	  that	  limit	  the	  negative	  side	  effects	  of	  commonly	  used	  therapies	  like	  interferon	  and	  ribavirin.	  As	  some	  studies	  of	  HIV	  have	  shown	  a	  ‘normalization’	  of	  DTI	  variables	  with	  HAART	  (Wright	  et	  al.,	  2012,	  Becker,	  2012)	  it	  would	  be	  beneficial	  to	  investigate	  changes	  in	  DTI	  parameters	  in	  these	  patients	  who	  currently	  are	  not	  on	  HCV	  treatment,	  or	  had	  a	  poor	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response	  to	  treatment	  to	  determine	  if	  DTI	  metrics	  become	  normalized	  after	  HCV	  treatment	  is	  initiated.	  If	  so,	  this	  may	  provide	  more	  information	  about	  the	  mechanisms	  associated	  with	  white	  matter	  abnormalities	  in	  co-­‐infection.	  	   The	  course	  of	  HAND	  has	  been	  defined	  as	  fluctuating,	  such	  that	  individuals	  may	  show	  deficits	  and	  improvements	  in	  cognitive	  function	  that	  change	  over	  the	  course	  of	  the	  disease.	  Recent	  longitudinal	  studies	  using	  neuroimaging	  have	  shown	  what	  appears	  to	  be	  a	  reconstitution	  of	  integrity	  in	  HIV+	  individuals	  with	  the	  commencement	  of	  HAART	  (Ances	  2012,	  Becker	  2012).	  It	  is	  possible	  that	  levels	  of	  inflammatory	  markers	  mediate	  changes	  in	  neuroimaging	  indices	  and	  neuropsychological	  performance	  throughout	  the	  course	  of	  disease.	  Additional	  longitudinal	  studies	  exploring	  the	  relationship	  between	  inflammation,	  neuroimaging,	  and	  neuropsychological	  performance	  are	  needed	  to	  further	  elucidate	  the	  relationship.	  It	  is	  also	  imperative	  to	  find	  anti-­‐inflammatory	  agents	  to	  minimize	  the	  impact	  on	  neural	  tissue	  in	  HIV	  and	  HCV,	  as	  an	  early	  effort	  to	  reduce	  inflammation	  using	  minocycline	  was	  not	  effective	  in	  improving	  cognitive	  function	  (Sacktor	  et	  al.,	  2011)	  	   In	  summary,	  this	  study	  identifies	  a	  significant	  impact	  of	  HIV/HCV+	  co-­‐infection	  on	  white	  matter	  microstructural	  integrity.	  Changes	  to	  DTI	  indices	  of	  FA	  and	  RD	  indicate	  an	  impact	  of	  co-­‐infection	  on	  the	  myelin,	  resulting	  in	  increased	  diffusion	  perpendicular	  to	  axon	  fibers	  primarily	  in	  the	  anterior	  regions	  of	  the	  CC.	  These	  changes	  had	  a	  trend	  level	  association	  with	  cognitive	  measures	  that	  rely	  on	  prefrontal	  and	  motor	  cortices,	  areas	  connected	  with	  the	  sections	  of	  the	  CC	  that	  were	  significantly	  altered.	  Although	  there	  was	  an	  effect	  of	  HIV	  mono-­‐infection	  on	  FA	  in	  the	  CC,	  the	  effect	  of	  co-­‐infection	  was	  stronger.	  Future	  studies	  should	  assess	  the	  impact	  of	  HCV	  mono-­‐infection	  as	  well	  as	  the	  impact	  of	  new	  HCV	  therapies	  on	  DTI	  metrics	  and	  neuropsychological	  function.	  	  	  	  




Group	  demographics	  and	  descriptive	  statistics	  	  	   Control	   HIV+	   HIV+/HCV+	   Significance	  AGE	  Mean	   46.32	   44.65	   49.48	   p	  =0.134	  SD	   10.18	   7.28	   5.06	  n	   25	   23	   21	  Education	  Mean	   13.44	   13.22	   12.45	   p=0.334	  SD	   2.40	   2.75	   1.83	  n	   25	   23	   21	  CD4abs	  Mean	   	  	   462.48	   488.4	   p=.78	  SD	   	  	   338.99	   249.65	  n	   	  	   23	   21	  HIVRNAViralLoad	  Mean	   	  	   19980.	   1005	   p=0.26	  IQR	   	  	   50-­‐72	   20-­‐121.5	  n	   	  	   23	   21	  NadirCD4	  Mean	   	  	   197.48	   150.76	   p=0.35	  SD	   	  	   186.13	   132.30	  n	   	  	   	  	   	  	  Years	  since	  HIV	  diagnosis	  Mean	   	  	   8.78	   13.81	   p=0.022	  SD	   	  	   6.08	   7.73	  n	   	  	   23	   21	  APRI	  Mean	   .	   0.2889	   0.7252	   p=0.001	  SD	   	  	   0.12605	   0.61205	  n	   	  	   23	   21	  	  	  	  	  	  	  	  	  	  	  




Self-­‐report	  drug	  use	  (KMSK)	  	  	   Control	   HIV+	   HIV/HCV+	   	  
Alcohol	  Mean	   8.6	   10.6111	   9.96	   p=0.19	  SD	   3.47051	   2.03322	   2.93655	  n	   10	   18	   25	  
Tobacco	  Mean	   9.6364	   8.5625	   8.64	   p=0.71	  SD	   2.11058	   2.94321	   4.41475	  n	   11	   16	   25	  
Cocaine	  Mean	   2.4	   10.2105	   10.64	   p<0.001	  SD	   4.37671	   5.12704	   5.31413	  n	   10	   19	   25	  
Heroine/Opiates	  Mean	   1.4444	   0.3125	   1.68	   p=.39	  SD	   4.33333	   0.87321	   3.60231	  n	   9	   16	   25	  
Marijuana	  Mean	   2.6154	   9.7222	   6.75	   p<0.001	  SD	   3.40437	   3.25044	   3.23365	  n	   13	   18	   24	  	  	  Table	  3	  
	  	  	  




	  Figure	  1	  Shows	  the	  significant	  differences	  across	  the	  groups	  for	  MD,	  FA,	  and	  RD	  in	  the	  corpus	  callosum	  





Figure 2 Shows the significant differences between groups in the Corpus Callosum (CC1 as highlighted 
on brain image) for RD, MD, and FA 





Figure 3  Shows the significant differences between groups in the Corpus Callosum (CC2 as highlighted 
on brain image) for RD, MD, and FA 





Figure 4 Shows the significant differences between groups in the Corpus Callosum (CC3 as highlighted 
on brain image) for RD, MD, and FA 
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  Figure	  5	  Shows the significant differences between groups in the Corpus Callosum (CC4 as highlighted 
on brain image) for RD, MD, and FA 	  





Figure 6 Shows the significant differences between groups in the Corpus Callosum (CC5 as highlighted 
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Figure 7 shows the significant relationship between MD in the corpus callosum and depression scores in 
the HIV+ and HIV/HCV+ group. The relationship is significantly stronger in the HIV/HCV+ group	  
y = 0.0038x + 0.843 
















y = 0.005x + 0.7917 
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  Figure	  8	  Shows	  the	  relationship	  between	  RD	  in	  the	  corpus	  callosum	  and	  time	  since	  diagnosis	  in	  the	  HIV+	  and	  HIV/HCV+	  group.	  The	  relationship	  was	  significant	  in	  the	  HIV+	  group	  only.	  	  	  
	  Fig.	  	  9	  Shows	  the	  significant	  relationship	  between	  scores	  of	  working	  memory	  and	  overall	  mental	  health	  as	  measured	  by	  the	  SF-­‐36	  in	  the	  HIV/HCV+	  group	  only.	  
y = 0.0051x + 0.5101 












Time Since Diagnosis 
HIV+ group 
y = 0.0028x + 0.5278 












Time Since Diagnosis 
HIV/HCV+ group 
y = -0.0825x + 0.0714 
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